DaVita (DVA) 10-Q 5 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	9 Months Ended
	Sep. 30, 2015	Oct. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	DVA
Entity Registrant Name	DAVITA HEALTHCARE PARTNERS INC.
Entity Central Index Key	927,066
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		211,000,000
Entity Public Float		$ 16.4

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Patient service revenues	$ 2,414,034	$ 2,242,533	$ 7,049,428	$ 6,543,880
Less: Provision for uncollectible accounts	(109,452)	(98,971)	(314,581)	(270,220)
Net patient service revenues	2,304,582	2,143,562	6,734,847	6,273,660
Capitated revenues	926,847	848,546	2,643,552	2,435,480
Other revenues	294,236	259,716	869,849	757,949
Total net revenues	3,525,665	3,251,824	10,248,248	9,467,089
Operating expenses and charges:
Patient care costs and other costs	2,501,015	2,326,534	7,309,703	6,752,844
General and administrative	353,492	322,822	1,047,318	905,519
Depreciation and amortization	162,062	149,196	474,694	437,682
Provision for uncollectible accounts	2,511	3,961	6,497	9,680
Equity investment income	(2,783)	(5,225)	(10,724)	(18,692)
Loss contingency accrual and settlement charge		17,000	495,000	17,000
Total operating expenses and charges	3,016,297	2,814,288	9,322,488	8,104,033
Operating income	509,368	437,536	925,760	1,363,056
Debt expense	(103,481)	(99,878)	(305,121)	(312,345)
Debt redemption and refinancing charges			(48,072)	(97,548)
Other income (loss), net	2,484	(1,246)	4,262	2,145
Income before income taxes	408,371	336,412	576,829	955,308
Income tax expense	147,064	116,628	183,893	342,366
Net income	261,307	219,784	392,936	612,942
Less: Net income attributable to noncontrolling interests	(45,435)	(35,662)	(117,204)	(97,848)
Net income attributable to DaVita HealthCare Partners Inc.	$ 215,872	$ 184,122	$ 275,732	$ 515,094
Earnings per share:
Basic net income per share attributable to DaVita HealthCare Partners Inc.	$ 1.02	$ 0.87	$ 1.30	$ 2.43
Diluted net income per share attributable to DaVita HealthCare Partners Inc.	$ 1	$ 0.85	$ 1.27	$ 2.38
Weighted average shares for earnings per share:
Basic	212,374,897	212,617,238	212,914,126	212,086,735
Diluted	216,691,461	217,236,493	217,421,213	216,695,033

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 261,307	$ 219,784	$ 392,936	$ 612,942
Unrealized (losses) gains on interest rate swap and cap agreements:
Unrealized (losses) gains on interest rate swap and cap agreements	(1,851)	537	(10,064)	(7,177)
Reclassifications of net swap and cap agreements realized losses into net income	771	1,403	2,372	9,759
Unrealized (losses) gains on investments:
Unrealized (losses) gains on investments	(1,651)	(392)	(1,368)	517
Reclassification of net investment realized gains into net income	(203)		(376)	(207)
Foreign currency translation adjustments	(7,023)	(13,838)	(19,883)	(11,871)
Other comprehensive loss	(9,957)	(12,290)	(29,319)	(8,979)
Total comprehensive income	251,350	207,494	363,617	603,963
Less: Comprehensive income attributable to noncontrolling interests	(45,435)	(35,662)	(117,204)	(97,848)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$ 205,915	$ 171,832	$ 246,413	$ 506,115

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
ASSETS
Cash and cash equivalents	$ 1,047,419	$ 965,241
Short-term investments	922,848	337,399
Accounts receivable, less allowance of $261,850 and $242,674	1,699,892	1,525,849
Inventories	173,050	136,085
Other receivables	416,932	400,916
Other current assets	175,715	186,842
Income tax receivable	48,963	83,839
Deferred income taxes	253,067	240,626
Total current assets	4,737,886	3,876,797
Property and equipment, net of accumulated depreciation of $2,305,141 and $2,029,506	2,621,918	2,469,099
Intangibles, net of accumulated amortization of $751,806 and $621,891	1,826,782	1,949,498
Equity investments	67,883	65,637
Long-term investments	90,393	89,389
Other long-term assets	62,387	77,000
Goodwill	9,487,579	9,415,295
Total assets	18,894,828	17,942,715
LIABILITIES AND EQUITY
Accounts payable	487,945	445,453
Other liabilities	632,331	510,223
Accrued compensation and benefits	835,518	698,475
Medical payables	340,143	314,347
Current portion of long-term debt	114,617	120,154
Total current liabilities	2,410,554	2,088,652
Long-term debt	9,082,096	8,383,280
Other long-term liabilities	406,035	389,806
Deferred income taxes	906,807	890,701
Total liabilities	12,805,492	11,752,439
Commitments and contingencies:
Noncontrolling interests subject to put provisions	$ 897,139	$ 829,965
Equity:
Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)
Common stock ($0.001 par value, 450,000,000 shares authorized; 216,632,600 and 215,640,968 shares issued and 211,009,593 and 215,640,968 shares outstanding, respectively)	$ 217	$ 216
Additional paid-in capital	1,106,342	1,108,211
Retained earnings	4,362,835	4,087,103
Treasury stock (5,623,007 shares)	(424,705)
Accumulated other comprehensive loss	(54,336)	(25,017)
Total DaVita HealthCare Partners Inc. shareholders’ equity	4,990,353	5,170,513
Noncontrolling interests not subject to put provisions	201,844	189,798
Total equity	5,192,197	5,360,311
Total liabilities and equity	$ 18,894,828	$ 17,942,715

CONSOLIDATED BALANCE SHEETS (u5

CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 261,850	$ 242,674
Property and equipment, accumulated depreciation	2,305,141	2,029,506
Intangibles, accumulated amortization	$ 751,806	$ 621,891
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	216,632,600	215,640,968
Common stock, shares outstanding	211,009,593	215,640,968
Treasury stock, shares	5,623,007

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 392,936	$ 612,942
Adjustments to reconcile net income to cash provided by operating activities:
Settlement charge and loss contingency accrual	495,000	17,000
Settlement payments	(493,775)
Depreciation and amortization	474,694	437,335
Debt redemption and refinancing charges	48,072	97,548
Stock-based compensation expense	42,794	44,323
Tax benefits from stock award exercises	31,069	45,527
Excess tax benefits from stock award exercises	(19,555)	(32,665)
Deferred income taxes	(1,994)	(2,167)
Equity investment income, net	10,563	6,007
Other non-cash charges and loss on disposal of assets	26,583	30,604
Changes in operating assets and liabilities, other than from acquisitions and divestitures:
Accounts receivable	(178,148)	16,610
Inventories	(35,856)	(25,198)
Other receivables and other current assets	54,924	7,563
Other long-term assets	1,940	2,622
Accounts payable	11,473	2,332
Accrued compensation and benefits	123,081	147,570
Other current liabilities	96,671	72,932
Income taxes	35,282	72,283
Other long-term liabilities	4,773	(23,770)
Net cash provided by operating activities	1,120,527	1,529,398
Cash flows from investing activities:
Additions of property and equipment	(462,213)	(443,507)
Acquisitions	(90,709)	(218,117)
Proceeds from asset and business sales	6,865	3,620
Purchase of investments available for sale	(6,667)	(7,138)
Purchase of investments held-to-maturity	(1,555,604)	(163,046)
Proceeds from sale of investments available for sale	1,961	1,321
Proceeds from investments held-to-maturity	969,549	27,781
Purchase of intangible assets		(50)
Purchase of equity investments	(13,623)	(32,483)
Distributions received on equity investments	57	434
Net cash used in investing activities	(1,150,384)	(831,185)
Cash flows from financing activities:
Borrowings	41,371,392	46,619,292
Payments on long-term debt and other financing costs	(40,732,075)	(46,587,984)
Deferred financing costs and debt redemption and refinancing costs	(59,354)	(122,154)
Purchase of treasury stock	(384,110)
Distributions to noncontrolling interests	(125,938)	(105,143)
Stock award exercises and other share issuances, net	19,802	14,524
Excess tax benefits from stock award exercises	19,555	32,665
Contributions from noncontrolling interests	28,212	38,083
Proceeds from sales of additional noncontrolling interests		3,777
Purchase of noncontrolling interests	(23,605)	(12,069)
Net cash provided by (used in) financing activities	113,879	(119,009)
Effect of exchange rate changes on cash and cash equivalents	(1,844)	1,582
Net increase in cash and cash equivalents	82,178	580,786
Cash and cash equivalents at beginning of the year	965,241	946,249
Cash and cash equivalents at end of the period	$ 1,047,419	$ 1,527,035

CONSOLIDATED STATEMENTS OF EQUI

CONSOLIDATED STATEMENTS OF EQUITY (unaudited) - USD ($) $ in Thousands	Total	Non- controlling Interests subject to put provisions	Common stock	Additional paid-in capital	Retained earnings	Treasury stock	Accumulated other comprehensive(loss)	Total	Non-controlling interests not subject to put provisions
Beginning Balance at Dec. 31, 2013		$ 697,300	$ 213	$ 1,070,922	$ 3,363,989		$ (2,645)	$ 4,432,479	$ 173,062
Beginning Balance (in shares) at Dec. 31, 2013			213,163,000
Comprehensive income:
Net income		88,425			723,114			723,114	51,791
Other comprehensive loss							(22,372)	(22,372)
Stock purchase shares issued				19,010				19,010
Stock purchase shares issued (in shares)			298,000
Stock unit shares issued			$ 1	(28)				(27)
Stock unit shares issued (in shares)			304,000
Stock-settled SAR shares issued			$ 2	(2)
Stock-settled SAR shares issued (in shares)			1,876,000
Stock-settled stock-based compensation expense				54,969				54,969
Excess tax benefits from stock awards exercised				45,271				45,271
Distributions to noncontrolling interests		(93,884)							(55,455)
Contributions from noncontrolling interests		41,876							22,779
Sales and assumptions of additional noncontrolling interests		25,220		355				355	4,165
Purchases from noncontrolling interests		(6,111)		(5,357)				(5,357)	(6,544)
Other reclassification				210				210
Changes in fair value of noncontrolling interests		77,139		(77,139)				(77,139)
Ending Balance at Dec. 31, 2014	$ 5,360,311	829,965	$ 216	1,108,211	4,087,103		(25,017)	5,170,513	189,798
Ending Balance (in shares) at Dec. 31, 2014	215,640,968		215,641,000
Comprehensive income:
Net income		74,221			275,732			275,732	42,983
Other comprehensive loss	$ (29,319)						(29,319)	(29,319)
Stock unit shares issued				5				5
Stock unit shares issued (in shares)			343,000
Stock-settled SAR shares issued			$ 1	(1)
Stock-settled SAR shares issued (in shares)			649,000
Stock-settled stock-based compensation expense				43,022				43,022
Excess tax benefits from stock awards exercised				19,555				19,555
Distributions to noncontrolling interests		(74,874)							(51,064)
Contributions from noncontrolling interests		14,951							13,261
Sales and assumptions of additional noncontrolling interests		12,031							6,866
Purchases from noncontrolling interests		(3,090)		(20,515)				(20,515)
Changes in fair value of noncontrolling interests		43,935		(43,935)				(43,935)
Ending Balance at Sep. 30, 2015	$ 5,192,197	$ 897,139	$ 217	$ 1,106,342	$ 4,362,835	$ (424,705)	$ (54,336)	4,990,353	$ 201,844
Ending Balance (in shares) at Sep. 30, 2015	211,009,593		216,633,000			(5,623,000)
Comprehensive income:
Purchase of treasury stock	$ (424,705)					$ (424,705)		$ (424,705)
Purchase of treasury stock (in shares)	(5,623,000)					(5,623,000)

Condensed consolidated interim

Condensed consolidated interim financial statements	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Condensed consolidated interim financial statements	1. Condensed consolidated interim financial statements The condensed consolidated interim financial statements included in this report are prepared by the Company without audit. In the opinion of management, all adjustments necessary for a fair presentation of the results of operations are reflected in these consolidated interim financial statements. All significant intercompany accounts and transactions have been eliminated. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. The most significant estimates and assumptions underlying these financial statements and accompanying notes generally involve revenue recognition and accounts receivable, contingencies, impairments of long-lived assets and goodwill, fair value estimates, accounting for income taxes, variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, long-term incentive program compensation and medical liability claims. The results of operations for the nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full year. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Prior year balances and amounts have been reclassified to conform to the current year presentation. The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued and has included all necessary adjustments and disclosures.

Earnings per share

Earnings per share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings per share	2. Earnings per share Basic net income per share is calculated by dividing net income attributable to the Company, adjusted for any change in noncontrolling interests redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding, net of shares held in escrow that under certain circumstances may be returned to the Company. Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units (under the treasury stock method) as well as contingently returnable shares held in escrow. The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share are as follows: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 Basic: Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 184,122 $ 275,732 $ 515,094 Weighted average shares outstanding during the period 214,569 214,810 215,108 214,280 Vested stock units — 1 — 1 Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger (2,194 ) (2,194 ) (2,194 ) (2,194 ) Weighted average shares for basic earnings per share calculation 212,375 212,617 212,914 212,087 Basic net income per share attributable to DaVita HealthCare Partners Inc. $ 1.02 $ 0.87 $ 1.30 $ 2.43 Diluted: Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 184,122 $ 275,732 $ 515,094 Weighted average shares outstanding during the period 214,569 214,810 215,108 214,280 Vested stock units — 1 — 1 Assumed incremental shares from stock plans 2,122 2,425 2,313 2,414 Weighted average shares for diluted earnings per share calculation 216,691 217,236 217,421 216,695 Diluted net income per share attributable to DaVita HealthCare Partners Inc. $ 1.00 $ 0.85 $ 1.27 $ 2.38 Anti-dilutive potential common shares excluded from calculation (1) 1,184 1,422 1,092 1,804 ______________ (1) Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Accounts receivable

Accounts receivable	9 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Accounts receivable	3. Accounts receivable Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the ultimate collectability of the Company’s accounts receivable, the Company analyzes its historical cash collection experience and trends for each of its government payors and commercial payors to estimate the adequacy of the allowance for doubtful accounts and the amount of the provision for uncollectible accounts. Management regularly updates its analysis based upon the most recent information available to determine its current provision for uncollectible accounts and the adequacy of its allowance for doubtful accounts. For receivables associated with dialysis patient services covered by government payors, like Medicare, the Company receives 80% of the payment directly from Medicare as established under the government’s bundled payment system and determines an appropriate allowance for doubtful accounts and provision for uncollectible accounts on the remaining balance due depending upon the Company’s estimate of the amounts ultimately collectible from other secondary coverage sources or from the patients. For receivables associated with services to patients covered by commercial payors that are either based upon contractual terms or for non-contracted health plan coverage, the Company provides an allowance for doubtful accounts by recording a provision for uncollectible accounts based upon its historical collection experience, potential inefficiencies in its billing processes and for which collectability is determined to be unlikely. Approximately 1 During the nine months ended September 30, 2015, the Company’s allowance for doubtful accounts increased by $19,176. This was primarily due to an increase in U.S. dialysis and lab provision for uncollectible accounts as a result of an increase in write-offs of certain balances. There were no unusual transactions impacting the allowance for doubtful accounts.

Investments in debt and equity

Investments in debt and equity securities and other investments	9 Months Ended
	Sep. 30, 2015
Investments Debt And Equity Securities [Abstract]
Investments in debt and equity securities and other investments	4. Investments in debt and equity securities and other investments Based on the Company’s intentions and strategy concerning investments in debt securities, the Company classifies certain debt securities as held-to-maturity and records them at amortized cost. Equity securities that have readily determinable fair values, including those of mutual funds, common stock and other debt securities, are classified as available-for-sale and recorded at fair value. The Company’s investments in securities consist of the following: September 30, 2015 December 31, 2014 Held to Available Held to Available maturity for sale Total maturity for sale Total Certificates of deposit and money market funds due within one year $ 921,648 $ — $ 921,648 $ 335,975 $ — $ 335,975 Investments in mutual funds and common stock — 31,343 31,343 — 28,123 28,123 $ 921,648 $ 31,343 $ 952,991 $ 335,975 $ 28,123 $ 364,098 Short-term investments $ 921,648 $ 1,200 $ 922,848 $ 335,975 $ 1,424 $ 337,399 Long-term investments — 30,143 30,143 — 26,699 26,699 $ 921,648 $ 31,343 $ 952,991 $ 335,975 $ 28,123 $ 364,098 The cost of the certificates of deposit and money market funds at September 30, 2015 and December 31, 2014 approximates their fair value. As of September 30, 2015 and December 31, 2014, the available-for-sale investments included $ 2,700 4,976 1,992 1,446 1,611 284 173 1,321 340 207 The investments in mutual funds classified as available-for-sale are held within a trust to fund existing obligations associated with several of the Company’s non-qualified deferred compensation plans. As of September 30, 2015, the Company held $ 5,000 Certain HCP entities are required to maintain minimum cash balances in order to comply with regulatory requirements in conjunction with medical claim reserves. As of September 30, 2015, this minimum cash balance was approximately $ 54,900

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	5. Goodwill Changes in goodwill by reportable segments were as follows: Other-ancillary U.S. dialysis and services and related lab services HCP strategic initiatives Consolidated total Balance at January 1, 2014 $ 5,469,473 $ 3,516,162 $ 227,339 $ 9,212,974 Acquisitions 143,021 48,649 29,844 221,514 Divestitures (1,851 ) — — (1,851 ) Foreign currency and other adjustments — (2,277 ) (15,065 ) (17,342 ) Balance at December 31, 2014 $ 5,610,643 $ 3,562,534 $ 242,118 $ 9,415,295 Acquisitions 21,910 27,665 39,558 89,133 Divestitures — (446 ) — (446 ) Foreign currency and other adjustments — — (16,403 ) (16,403 ) Balance at September 30, 2015 $ 5,632,553 $ 3,589,753 $ 265,273 $ 9,487,579 Each of the Company’s operating segments described in Note 17 to these condensed consolidated financial statements represents an individual reporting unit for goodwill impairment testing purposes, except that each sovereign jurisdiction within the Company’s international operating segments is considered a separate reporting unit. Within the U.S. dialysis and related lab services operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit. The Company has applied a similar aggregation to the HCP operations in each region, to the vascular access service centers in its vascular access services reporting unit, to the physician practices in its physician services reporting unit, and to the dialysis centers within each sovereign international jurisdiction. For the Company’s additional operating segments, no component below the operating segment level is considered a discrete business and therefore these operating segments directly constitute individual reporting units. HCP’s current and expected future operating results have eroded, primarily as a result of recent reductions in its Medicare Advantage reimbursement rates, including the Medicare Advantage final benchmark rates for 2016 announced on April 6, 2015. As a result, the Company has determined that three of its HCP reporting units, HCP California, HCP Nevada and HCP New Mexico, remain at risk of goodwill impairment. As of September 30, 2015, HCP California, HCP Nevada and HCP New Mexico have goodwill of $2,518,569, $520,968, and $71,684, respectively. The Company prepared valuation updates, informed by third-party assistance, for these three businesses as of September 30, 2015, which indicate that the estimated fair values of HCP California, HCP Nevada and HCP New Mexico exceed their total carrying values by approximately 15.2%, 8.8% and 16.2%, respectively. Further reductions in HCP’s reimbursement rates or other significant adverse changes in its expected future cash flows or valuation assumptions could result in a goodwill impairment charge in the future. For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 1.8%, 1.9% and 2.1%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 4.6%, 3.4% and 3.9%, respectively. During the first nine months of 2015, the Company recorded an immaterial

Health care costs payable

Health care costs payable	9 Months Ended
	Sep. 30, 2015
Health Care Organizations [Abstract]
Health care costs payable	6. Health care costs payable The following table includes estimates for the cost of professional medical services provided by non-employed physicians and other providers, as well as inpatient and other ancillary costs for all markets other than California. The Company does not include inpatient and other ancillary costs for contracts held by its California licensed health plan and for contracts held by its California medical group entities; only professional medical services are included as state regulation does not allow those medical group entities to assume risk for inpatient services. Health care costs payable are included in medical payables in the condensed consolidated balance sheet. The following table shows the components of changes in health care costs payable for the nine months ended September 30, 2015: Nine months ended September 30, 2015 Health care costs payable, beginning of the period $ 214,405 Add: Components of incurred health care costs Current year 1,193,444 Prior years (1,327 ) Total incurred health care costs 1,192,117 Less: Claims paid Current year 1,008,193 Prior years 195,460 Total claims paid 1,203,653 Health care costs payable, end of the period $ 202,869 The Company’s prior year estimates of health care costs payable decreased by $1,327 resulting from certain medical claims being settled for amounts less than originally estimated. When significant increases (decreases) in prior-year health care cost estimates occur that the Company believes significantly impacts its current year operating results, the Company discloses that amount as unfavorable (favorable) development of prior-year’s health care cost estimates. Actual claim payments for prior year services have not been materially different from the Company’s year-end estimates.

Income taxes

Income taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income taxes	7. Income taxes As of September 30, 2015, the Company’s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $36,004, all of which would impact the Company’s effective tax rate if recognized. This balance represents an increase of $4,127 from the December 31, 2014 balance of $31,877. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. At September 30, 2015 and December 31, 2014, the Company had approximately $10,174 and $10,123, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefits.

Long-term debt

Long-term debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long-term debt	8. Long-term debt Long-term debt was comprised of the following: September 30, December 31, 2015 2014 Senior Secured Credit Facilities: Term Loan A $ 937,500 $ 975,000 Term Loan B 3,456,250 3,482,500 Senior notes 4,500,000 3,775,000 Acquisition obligations and other notes payable 61,348 69,045 Capital lease obligations 255,897 218,097 Total debt principal outstanding 9,210,995 8,519,642 Discount on long-term debt (14,282 ) (16,208 ) 9,196,713 8,503,434 Less current portion (114,617 ) (120,154 ) $ 9,082,096 $ 8,383,280 Scheduled maturities of long-term debt at September 30, 2015 were as follows: 2015 (remainder of the year) 29,880 2016 119,395 2017 149,372 2018 160,391 2019 734,892 2020 58,790 Thereafter 7,958,275 During the first nine months of 2015, the Company made mandatory principal payments under its Senior Secured Credit Facilities totaling $37,500 on the Term Loan A and $ 26,250 In April 2015, the Company issued $1,500,000 5.0% Senior Notes due 2025 (the 5.0% Senior Notes). The 5.0% Senior Notes pay interest on May 1 and November 1 of each year beginning November 1, 2015. The 5.0% Senior Notes are unsecured senior obligations and rank equally in right of payment with the Company’s existing and future unsecured senior indebtedness. The 5.0% Senior Notes are guaranteed by certain of the Company’s domestic subsidiaries. The Company may redeem up to 35% of the 5.0% Senior Notes at any time prior to May 1, 2018 at a certain specified price from the proceeds of one or more equity offerings. In addition, the Company may redeem some or all of the 5.0% Senior Notes at any time prior to May 1, 2020 at make whole redemption prices and on or after such date at certain specified redemption rates. The proceeds from the 5.0% Senior Notes were used to repurchase all of the outstanding principal balances of the $775,000 6 ⅝% Senior Notes due 2020 (the 6 ⅝% Notes) through a combination of a tender offer and a redemption process and to pay fees and expenses. The remaining proceeds may be used for general corporate purposes, future acquisitions and share repurchases. As a result of these transactions, the Company incurred $ 48,072 The Company has entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall interest rate risk management strategy. These agreements are not held for trading or speculative purposes and have the economic effect of converting the LIBOR variable component of the Company’s interest rate to a fixed rate. These swap agreements are designated as cash flow hedges, and as a result, hedge-effective gains or losses resulting from changes in the fair values of these swaps are reported in other comprehensive income until such time as the hedged forecasted cash flows occur, at which time the amounts are reclassified into net income. Net amounts paid or received for each specific swap tranche that have settled have been reflected as adjustments to debt expense. In addition, the Company has entered into several active and forward interest rate cap agreements that have the economic effect of capping the Company’s maximum exposure to LIBOR variable interest rate changes on specific portions of the Company’s floating rate debt, as described below. The cap agreements are also designated as cash flow hedges and, as a result, changes in the fair values of these cap agreements are reported in other comprehensive income. The amortization of the original cap premium is recognized as a component of debt expense on a straight-line basis over the term of the cap agreements. The swap and cap agreements do not contain credit-risk contingent features. As of September 30, 2015, the Company maintains several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts totaling $783,750. These agreements have the economic effect of modifying the LIBOR variable component of the Company’s interest rate on an equivalent amount of the Company’s Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26 2.00 2,061 914 $4,798 914 As of September 30, 2015, the Company maintains several forward interest rate cap agreements that were entered into in November 2014 with notional amounts totaling $3,500,000. These forward cap agreements will be effective September 30, 2016 and will have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent amount of the Company’s debt. The cap agreements expire on June 30, 2018. As of September 30, 2015, the total fair value of these cap agreements was an asset of approximately $ 2,176 10,164 As of September 30, 2015, the Company maintains several active interest rate cap agreements that were entered into in March 2013 with notional amounts totaling $2,735,000 on the Company’s Term Loan B debt. These agreements have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 2.50% on an equivalent amount of the Company’s Term Loan B. During the nine months ended September 30, 2015, the Company recognized debt expense of $ 1,829 1,551 In October 2015, the Company entered into several forward interest rate cap agreements with notional amounts totaling $3,500,000. These forward cap agreements will be effective June 29, 2018 and will have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent amount of its debt. These cap agreements expire on June 30, 2020. The following table summarizes the Company’s derivative instruments as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Derivatives designated as hedging Balance sheet Balance sheet instruments location Fair value location Fair value Interest rate swap agreements Other short-term liabilities $ 914 Other short-term liabilities $ 1,457 Interest rate swap agreements Other long-term assets $ — Other long-term assets $ 3,281 Interest rate cap agreements Other long-term assets $ 2,219 Other long-term assets $ 13,934 The following table summarizes the effects of the Company’s interest rate swap and cap agreements for the three and nine months ended September 30, 2015 and 2014: Amount of Amount of (losses) gains recognized in losses reclassified OCI on interest rate swap from accumulated and cap agreements Location of OCI into income Three months ended Nine months ended losses reclassified Three months ended Nine months ended Derivatives designated September 30, September 30, from accumulated September 30, September 30, as cash flow hedges 2015 2014 2015 2014 OCI into income 2015 2014 2015 2014 Interest rate swap agreements $ (1,128 ) $ 1,058 $ (4,798 ) $ (6,728 ) Debt expense $ (655 ) $ (795 ) $ (2,061 ) $ (11,495 ) Interest rate cap agreements (1,909 ) (178 ) (11,715 ) (5,052 ) Debt expense (609 ) (1,507 ) (1,829 ) (4,521 ) Tax benefit (expense) 1,186 (343 ) 6,449 4,603 493 899 1,518 6,257 Total $ (1,851 ) $ 537 $ (10,064 ) $ (7,177 ) $ (771 ) $ (1,403 ) $ (2,372 ) $ (9,759 ) As of September 30, 2015, the interest rate on the Company’s Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date. The Term Loan B is also subject to interest rate caps if LIBOR should rise above 2.50%. See above for further details. Interest rates on the Company’s senior notes are fixed by their terms. The LIBOR variable component of the Company’s interest rate on a majority of the Company’s Term Loan A is economically fixed as a result of interest rate swaps. As a result of embedded LIBOR floors on the Term Loan B debt agreement and the swap and cap agreements, the Company’s overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.50 2.00 2.75 The Company’s overall weighted average effective interest rate during the third quarter of 2015 was 4.40 4.40 As of September 30, 2015, the Company had undrawn revolving credit facilities totaling $1,000,000 40,000 56,000 1,000

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Contingencies	9. Contingencies The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors. Inquiries by the Federal Government and Certain Related Civil Proceedings Vainer Private Civil Suit qui tam 2011 U.S. Attorney Medicaid Investigation Swoben Private Civil Suit qui tam qui tam 2015 U.S. Attorney Transportation Investigation 2015 U.S. OIG Medicare Advantage Civil Investigation In addition to the subpoena described above, in June 2015, the Company received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company’s and its subsidiaries’ (including HealthCare Partners and its subsidiary JSA HealthCare Corporation) provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into Medicare Advantage patient diagnosis coding and risk adjustment practices and potential overpayments by the government. Some of the information requested relates to what the Company disclosed in the risk factors of the Company’s quarterly report on Form 10-Q for the first quarter of 2015 as a potentially improper historical HCP coding practice related to a particular condition. The practice in question was discontinued following the Company’s November 1, 2012 acquisition of HCP and, as the Company previously disclosed, the Company notified CMS of the coding practice and potential overpayments. In connection with the HCP merger, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company would pursue an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred. The Company can make no assurances that the indemnification and escrow would cover the full amount of the Company’s potential losses related to this matter. The Company is cooperating with the government and will gather and produce the requested information. Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and if criminal proceedings were initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any. Shareholder Derivative Claims DaVita HealthCare Partners Inc. Derivative Litigation qui tam qui tam Other The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any. A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court’s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company’s condensed consolidated financial statements. In June 2015, the Company reached an agreement in principle to resolve the remainder of the claims in this litigation. The settlement must be approved by the court, and the parties are in the process of seeking that approval. The amount of the settlement is not material to the Company’s condensed consolidated financial statements. In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.

Noncontrolling interests subjec

Noncontrolling interests subject to put provisions and other commitments	9 Months Ended
	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Noncontrolling interests subject to put provisions and other commitments	10. Noncontrolling interests subject to put provisions and other commitments The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its majority-owned joint ventures, non-owned and minority-owned entities. These obligations are in the form of put provisions and are exercisable at the third-party owners’ discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners’ noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company’s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled could vary significantly depending upon market conditions including potential purchasers’ access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners’ noncontrolling interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value are immaterial. The Company has certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment as well as to physician-owned vascular access clinics or medical practices that the Company operates under management and administrative services agreements of approximately $1,000. Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years. Accordingly, the noncontrolling interests in these joint ventures are considered mandatorily redeemable instruments, for which the classification and measurement requirements have been indefinitely deferred. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.

Long-term incentive compensatio

Long-term incentive compensation	9 Months Ended
	Sep. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Long-term incentive compensation	11. Long-term incentive compensation Long-term incentive program (LTIP) compensation includes both stock-based awards (principally stock-settled stock appreciation rights, restricted stock units and performance stock units) as well as long-term performance-based cash awards. Long-term incentive compensation expense, which was primarily general and administrative in nature, was attributed to the dialysis and related lab services business, the HCP business, corporate support costs, and the ancillary services and strategic initiatives. The Company’s stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. During the nine months ended September 30, 2015, the Company granted 920 stock-settled stock appreciation rights with an aggregate grant-date fair value of $16,763 and a weighted-average expected life of approximately 4.1 years, and also granted 272 stock units with an aggregate grant-date fair value of $21,933 and a weighted-average expected life of approximately 3.1 years. For the nine months ended September 30, 2015 and 2014, the Company recognized $100,171 and $88,323, respectively, in total LTIP expense, of which $42,794 and $44,323, respectively, represented stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation for the nine months ended September 30, 2015 and 2014 was $14,870 and $16,075, respectively. As of September 30, 2015, the Company had $145,914 of total estimated unrecognized compensation cost for outstanding LTIP awards, including $75,635 related to stock-based compensation arrangements under the Company’s equity compensation and stock purchase plans. The Company expects to recognize the performance-based cash component of these LTIP costs over a weighted average remaining period of 1.1 years and the stock-based component of these LTIP costs over a weighted average remaining period of 1.3 years. For the nine months ended September 30, 2015 and 2014, the Company received $31,069 and $45,527, respectively, in actual tax benefits upon the exercise of stock awards.

Share repurchases

Share repurchases	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Share Repurchases	12. Share repurchases During the three months ended September 30, 2015, the Company repurchased a total of 4,556 shares of its common stock for $340,592, or an average price of $74.76 per share. During the nine months ended September 30, 2015, the Company repurchased a total of 5,623 shares of its common stock for $424,705, or an average price of $75.53 per share. The Company also repurchased a total of 2 shares of its common stock subsequent to September 30, 2015 for $156, or an average price of $71.01 per share. On April 14, 2015, the Company’s Board of Directors approved additional share repurchases in the amount of $725,944. These share repurchases are in addition to the $274,056 remaining under the Company’s Board of Directors’ prior share repurchase approval announced on November 4, 2010. As a result of these transactions, the Company now has a total of $659,252 in outstanding authorizations available for share repurchases as of October 30, 2015. These share repurchase authorizations have no expiration dates. However, the Company is subject to share repurchase limitations under the terms of its Senior Secured Credit Facilities and the indentures governing its Senior Notes.

Comprehensive income

Comprehensive income	9 Months Ended
	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Comprehensive income	1 3 . Comprehensive income For the three months ended For the nine months ended September 30, 2015 September 30, 2015 Interest Foreign Accumulated Interest Foreign Accumulated rate swap currency other rate swap currency other and cap Investment translation comprehensive and cap Investment translation comprehensive agreements securities adjustments (loss) income agreements securities adjustments (loss) income Beginning balance $ (8,407 ) $ 3,261 $ (39,233 ) $ (44,379 ) $ (1,795 ) $ 3,151 $ (26,373 ) $ (25,017 ) Unrealized losses (3,037 ) (2,325 ) (7,023 ) (12,385 ) (16,513 ) (1,864 ) (19,883 ) (38,260 ) Related income tax benefit 1,186 674 — 1,860 6,449 496 — 6,945 (1,851 ) (1,651 ) (7,023 ) (10,525 ) (10,064 ) (1,368 ) (19,883 ) (31,315 ) Reclassification from accumulated other comprehensive income into net income 1,264 (333 ) — 931 3,890 (617 ) — 3,273 Related income tax (expense) benefit (493 ) 130 — (363 ) (1,518 ) 241 — (1,277 ) 771 (203 ) — 568 2,372 (376 ) — 1,996 Ending balance $ (9,487 ) $ 1,407 $ (46,256 ) $ (54,336 ) $ (9,487 ) $ 1,407 $ (46,256 ) $ (54,336 ) For the three months ended For the nine months ended September 30, 2014 September 30, 2014 Interest Foreign Accumulated Interest Foreign Accumulated rate swap currency other rate swap currency other and cap Investment translation comprehensive and cap Investment translation comprehensive agreements securities adjustments income (loss) agreements securities adjustments (loss) income Beginning balance $ (1,702 ) $ 3,822 $ (1,454 ) $ 666 $ (2,344 ) $ 3,120 $ (3,421 ) $ (2,645 ) Unrealized gains (losses) 880 (567 ) (13,838 ) (13,525 ) (11,780 ) 838 (11,871 ) (22,813 ) Related income tax (expense) benefit (343 ) 175 — (168 ) 4,603 (321 ) — 4,282 537 (392 ) (13,838 ) (13,693 ) (7,177 ) 517 (11,871 ) (18,531 ) Reclassification from accumulated other comprehensive income into net income 2,302 — — 2,302 16,016 (340 ) — 15,676 Related income tax (expense) benefit (899 ) — — (899 ) (6,257 ) 133 — (6,124 ) 1,403 — — 1,403 9,759 (207 ) — 9,552 Ending balance $ 238 $ 3,430 $ (15,292 ) $ (11,624 ) $ 238 $ 3,430 $ (15,292 ) $ (11,624 ) The reclassification of net swap and cap realized losses into income are recorded as debt expense in the corresponding condensed consolidated statements of income. See Note 8 to the condensed consolidated financial statements for further details. The reclassification of net investment realized gains into income are recorded in other income in the corresponding condensed consolidated statements of income. See Note 4 to the condensed consolidated financial statements for further details.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Acquisitions	1 4 . Acquisitions On August 17, 2015, the Company entered into a definitive agreement to acquire Colorado-based Renal Ventures Limited, LLC (Renal Ventures), including a 100 percent interest in all dialysis centers owned by Renal Ventures, for approximately $415,000 in cash, subject to, among other things, adjustments for certain items such as working capital. Renal Ventures currently operates 36 dialysis clinics in six states serving approximately 2,400 patients, and also operates other ancillary businesses. The transaction is subject to approval by the Federal Trade Commission (FTC) including Hart-Scott-Rodino antitrust clearance. The Company anticipates that it will be required by the FTC to divest a certain number of outpatient dialysis centers as a condition of the transaction. The Company currently expects the transaction to close in early 2016. During the nine months ended September 30, 2015, the Company acquired dialysis businesses and other businesses consisting of six dialysis centers located in the U.S., seven The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values: Nine months ended September 30, 2015 Current assets $ 3,324 Property and equipment 12,040 Amortizable intangible and other long-term assets 8,478 Goodwill 89,133 Long-term deferred income taxes (750 ) Noncontrolling interests assumed (18,898 ) Liabilities assumed (1,788 ) Aggregate purchase price $ 91,539 Amortizable intangible assets acquired during the first nine months of 2015 had weighted-average estimated useful lives of nine ten three Contingent earn-out obligations The Company has several contingent earn-out obligations associated with acquisitions that could result in the Company paying the former shareholders of acquired companies a total of up to $ 133,791 one three Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the re-measurement recorded in earnings. See Note 16 30,309 21,915 8,394 The following is a reconciliation of changes in the contingent earn-out obligations for the nine months ended September 30, 2015: Beginning balance, January 1, 2015 $ 39,129 Remeasurement of fair value for contingent earn-out obligations (2,818 ) Payments on contingent earn-out obligations (6,002 ) $ 30,309

Variable interest entities

Variable interest entities	9 Months Ended
	Sep. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Variable interest entities	1 5 . Variable interest entities The Company relies on the operating activities of certain entities that it does not directly own or control, but over which it has indirect influence and of which it is considered the primary beneficiary. These entities are subject to the consolidation guidance applicable to variable interest entities (VIEs). Under U.S. generally accepted accounting principles (GAAP), VIEs typically include (i) entities for which the entity’s equity is not sufficient to finance its activities without additional subordinated financial support; (ii) entities for which the equity holders as a group lack the power to direct the activities that most significantly influence the entity’s economic performance, the obligation to absorb the entity’s expected losses, or the right to receive the entity’s expected returns; or (iii) entities for which the voting rights of some investors are not proportional to their obligations to absorb the entity’s losses. Under U.S. GAAP, the Company has determined that substantially all of the entities it is associated with that qualify as VIEs must be included in its consolidated financial statements. The Company manages these entities and provides operating and capital funding as necessary for these entities to accomplish their operational and strategic objectives. A number of these entities are subject to nominee share ownership or share transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. In other cases the Company’s management agreements with these entities include both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for the entities to the Company. In some cases such entities are subject to broad exclusivity or noncompetition restrictions that benefit the Company. Further, in some cases the Company has contractual arrangements with its related party nominee owners that effectively indemnify these parties from the economic losses from, or entitle the Company to the economic benefits of, these entities. The analyses upon which these consolidation determinations rest are complex, involve uncertainties, and require significant judgment on various matters, some of which could be subject to different interpretations. At September 30, 2015, these condensed consolidated financial statements include total assets of VIEs of $652,690 and total liabilities and noncontrolling interests of VIEs to third parties of $337,476. The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and the Company consolidates each of these plans as their primary beneficiary. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities recorded in accrued compensation and benefits and other long-term liabilities. See Note 4 for disclosures on the assets of these consolidated non-qualified deferred compensation plans.

Fair value of financial instrum

Fair value of financial instruments	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair value of financial instruments	1 6 . Fair value of financial instruments The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company also has classified certain assets, liabilities and temporary equity that are measured at fair value into the appropriate fair value hierarchy levels as defined by the FASB. The following table summarizes the Company’s assets, liabilities and temporary equity measured at fair value on a recurring basis as of September 30, 2015: Quoted prices in Significant active Significant other unobservable identical assets observable inputs Total (Level 1) (Level 2) (Level 3) Assets Available-for-sale securities $ 31,343 $ 31,343 $ — $ — Interest rate cap agreements $ 2,219 $ — $ 2,219 $ — Interest rate swap agreements $ — $ — $ — $ — Funds on deposit with third parties $ 87,710 $ 87,710 $ — $ — Liabilities Contingent earn-out obligations $ 30,309 $ — $ — $ 30,309 Interest rate swap agreements $ 914 $ — $ 914 — Temporary equity Noncontrolling interests subject to put provisions $ 897,139 $ — $ — $ 897,139 The available-for-sale securities represent investments in various open-ended registered investment companies, or mutual funds, and are recorded at estimated fair value based upon quoted prices reported by each mutual fund. See Note 4 The interest rate swap and cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate swap and cap agreements would be materially different from the fair value estimates currently reported. See Note 8 The funds on deposit with third parties represent funds held with various third parties as required by regulation or contract and invested by those parties in various investments, which are measured at estimated fair value based primarily on quoted market prices. The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs including projected EBITDA, estimated probability of achieving gross margins or quality margins of certain medical procedures and the estimated probability of earn-out payments being made using an option pricing technique and a simulation model for expected EBITDA and operating income. In addition, a probability adjusted model was used to estimate the fair value amounts of the quality margins. The estimated fair value of these contingent earn-out obligations are remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. See Note 10 to these condensed consolidated financial statements for a discussion of the Company’s methodology for estimating the fair value of noncontrolling interests subject to put obligations. Other financial instruments consist primarily of cash, accounts receivable, life insurance contracts, accounts payable, other accrued liabilities and debt. The balances of the non-debt financial instruments are presented in the consolidated financial statements at September 30, 2015 at their approximate fair values due to the short-term nature of their settlements. The carrying balance of the Company’s Senior Secured Credit Facilities totaled $ 4,393,750 4,382,766 4,459,375 4,500,000

Segment reporting

Segment reporting	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment reporting	17. Segment reporting The Company operates two major divisions, Kidney Care and HCP. The Kidney Care division is comprised of the Company’s U.S. dialysis and related lab services business, various other ancillary services and strategic initiatives, including its international dialysis operations, and the Company’s corporate support costs. The Company’s U.S. dialysis and related lab services business is the Company’s largest line of business, and is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as ESRD. The Company’s HCP division is a patient- and physician-focused integrated health care delivery and management company with nearly three decades of providing coordinated outcomes-based medical care in a cost-effective manner. The Company’s ancillary services and strategic initiatives consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care and the Company’s international dialysis operations. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker in making decisions about allocating resources to and assessing the financial results of the Company’s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer. The Company’s separate operating segments include its U.S. dialysis and related lab services business, its HCP operations in each region, each of its ancillary services and strategic initiatives, and its international operations in the European, Middle Eastern, Asia Pacific, and Latin American regions. The U.S. dialysis and related lab services business and the HCP business each qualify as separately reportable segments, and all of the other ancillary services and strategic initiatives operating segments, including the international operating segments, have been combined and disclosed in the other segments category. The Company’s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial results of the operating segments. For internal management reporting, segment operations include direct segment operating expenses but exclude corporate support costs, which consist primarily of indirect labor, benefits and long-term incentive based compensation of certain departments which provide support to all of the Company’s various operating lines of business. Corporate support costs are reduced by internal management fees received from the Company’s ancillary lines of businesses. The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 Segment net revenues: U.S. dialysis and related lab services Patient service revenues: External sources $ 2,287,329 $ 2,153,914 $ 6,679,251 $ 6,279,263 Intersegment revenues 13,630 10,701 39,078 27,617 Total dialysis and related lab services revenues 2,300,959 2,164,615 6,718,329 6,306,880 Less: Provision for uncollectible accounts (103,543 ) (91,996 ) (302,324 ) (257,687 ) Net dialysis and related lab services patient service revenues 2,197,416 2,072,619 6,416,005 6,049,193 Other revenues (1) 3,490 3,427 10,214 10,159 Total net dialysis and related lab services revenues 2,200,906 2,076,046 6,426,219 6,059,352 HCP HCP revenues: Capitated revenues 906,478 827,933 2,587,545 2,382,656 Net patient service revenues 78,938 49,783 241,385 164,081 Other revenues (2) 15,536 14,013 66,124 72,566 Intersegment capitated and other revenues 84 251 96 608 Total revenues 1,001,036 891,980 2,895,150 2,619,911 Other—Ancillary services and strategic initiatives Net patient service revenues 41,858 31,860 116,535 88,003 Capitated revenues 20,369 20,613 56,007 52,824 Other external sources 275,210 242,277 793,511 675,224 Intersegment revenues 7,385 4,995 18,079 14,287 Total ancillary services and strategic initiatives revenues 344,822 299,745 984,132 830,338 Total net segment revenues 3,546,764 3,267,771 10,305,501 9,509,601 Elimination of intersegment revenues (21,099 ) (15,947 ) (57,253 ) (42,512 ) Consolidated net revenues $ 3,525,665 $ 3,251,824 $ 10,248,248 $ 9,467,089 Segment operating margin (loss): U.S. dialysis and related lab services $ 461,899 $ 400,226 $ 795,255 $ 1,194,874 HCP 82,562 46,339 215,192 182,341 Other—Ancillary services and strategic initiatives (30,118 ) (5,502 ) (70,153 ) (5,744 ) Total segment operating margin 514,343 441,063 940,294 1,371,471 Reconciliation of segment operating margin to consolidated income before income taxes: Corporate support costs (4,975 ) (3,527 ) (14,534 ) (8,415 ) Consolidated operating income 509,368 437,536 925,760 1,363,056 Debt expense (103,481 ) (99,878 ) (305,121 ) (312,345 ) Debt redemption and refinancing charges (48,072 ) (97,548 ) Other income (loss), net 2,484 (1,246 ) 4,262 2,145 Consolidated income before income taxes $ 408,371 $ 336,412 $ 576,829 $ 955,308 (1) (2) 50 Depreciation and amortization expense by reportable segment is as follows: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 U.S. dialysis and related lab services $ 111,828 $ 101,870 $ 326,281 $ 297,477 HCP 43,523 42,558 129,890 126,555 Ancillary services and strategic initiatives 6,711 4,768 18,523 13,650 $ 162,062 $ 149,196 $ 474,694 $ 437,682 Summary of assets by reportable segment is as follows: September 30, December 31, 2015 2014 Segment assets U.S. dialysis and related lab services (including equity investments of $29,784 and $28,138, respectively) $ 11,752,159 $ 10,959,096 HCP (including equity investments of $16,618 and $15,393, respectively) 6,403,622 6,285,984 Other—Ancillary services and strategic initiatives (including equity investments of $21,481 and $22,106, respectively) 739,047 697,635 Consolidated assets $ 18,894,828 $ 17,942,715 Expenditures for property and equipment by reportable segment is as follows: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 U.S. dialysis and related lab services. $ 138,683 $ 149,247 $ 385,734 $ 399,114 HCP 18,885 6,121 36,870 16,401 Ancillary services and strategic initiatives 13,772 9,546 39,609 27,992 $ 171,340 $ 164,914 $ 462,213 $ 443,507

Changes in DaVita HealthCare Pa

Changes in DaVita HealthCare Partners Inc.'s ownership interest in consolidated subsidiaries	9 Months Ended
	Sep. 30, 2015
Noncontrolling Interest [Abstract]
Changes in DaVita HealthCare Partners Inc.'s ownership interest in consolidated subsidiaries	18. Changes in DaVita HealthCare Partners Inc.’s ownership interest in consolidated subsidiaries The effects of changes in DaVita HealthCare Partners Inc.’s ownership interest on the Company’s equity are as follows: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 184,122 $ 275,732 $ 515,094 (Decrease) increase in paid-in capital for sales of noncontrolling interests — (316 ) — 355 Decrease in paid-in capital for the purchase of noncontrolling interests and adjustments to ownership interest (12,094 ) (1,962 ) (20,515 ) (506 ) Net transfers to noncontrolling interests (12,094 ) (2,278 ) (20,515 ) (151 ) Net income attributable to DaVita HealthCare Partners Inc., net of transfers to noncontrolling interests $ 203,778 $ 181,844 $ 255,217 $ 514,943

New accounting standards

New accounting standards	9 Months Ended
	Sep. 30, 2015
Accounting Changes And Error Corrections [Abstract]
New accounting standards	1 9 . New accounting standards In September 2015, the FASB issued Accounting Standards Update (ASU) No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Interest – Imputation of Interest (Subtopic 835-30) – Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date.

Condensed consolidating financi

Condensed consolidating financial statements	9 Months Ended
	Sep. 30, 2015
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Condensed consolidating financial statements	20 . Condensed consolidating financial statements The following information is presented in accordance with Rule 3-10 of Regulation S-X. The operating and investing activities of the separate legal entities included in the Company’s consolidated financial statements are fully interdependent and integrated. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other administrative services. The Company’s senior notes are guaranteed by substantially all of its domestic wholly-owned subsidiaries. Each of the guarantor subsidiaries has guaranteed the notes on a joint and several basis. However, the guarantor subsidiaries can be released from their obligations in the event of a sale or other disposition of all or substantially all of the assets of such subsidiary, including by merger or consolidation or the sale of all equity interests in such subsidiary owned by the Company, if such subsidiary guarantor is designated as an unrestricted subsidiary or otherwise ceases to be a restricted subsidiary, and if such subsidiary guarantor no longer guaranties any other indebtedness of the Company. Non-wholly-owned subsidiaries, certain wholly-owned subsidiaries, foreign subsidiaries, joint ventures, partnerships, non-owned entities and third parties are not guarantors of these obligations. Condensed Consolidating Statements of Income DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 1,656,648 $ 795,325 $ (37,939 ) $ 2,414,034 Less: Provision for uncollectible accounts — (78,494 ) (30,958 ) — (109,452 ) Net patient service revenues — 1,578,154 764,367 (37,939 ) 2,304,582 Capitated revenues — 453,766 473,196 (115 ) 926,847 Other revenues 184,561 480,412 7,869 (378,606 ) 294,236 Total net revenues 184,561 2,512,332 1,245,432 (416,660 ) 3,525,665 Operating expenses 110,935 2,244,237 1,077,785 (416,660 ) 3,016,297 Operating income 73,626 268,095 167,647 — 509,368 Debt expense, including debt refinancing charges (102,136 ) (83,037 ) (9,766 ) 91,458 (103,481 ) Other income 89,824 2,379 1,739 (91,458 ) 2,484 Income tax expense 25,368 112,310 9,386 — 147,064 Equity earnings in subsidiaries 179,926 104,799 — (284,725 ) — Net income 215,872 179,926 150,234 (284,725 ) 261,307 Less: Net income attributable to noncontrolling interests — — — (45,435 ) (45,435 ) Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 179,926 $ 150,234 $ (330,160 ) $ 215,872 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 1,592,398 $ 683,171 $ (33,036 ) $ 2,242,533 Less: Provision for uncollectible accounts — (61,973 ) (36,998 ) — (98,971 ) Net patient service revenues — 1,530,425 646,173 (33,036 ) 2,143,562 Capitated revenues — 442,472 406,926 (852 ) 848,546 Other revenues 174,226 422,733 5,821 (343,064 ) 259,716 Total net revenues 174,226 2,395,630 1,058,920 (376,952 ) 3,251,824 Operating expenses 123,856 2,126,918 940,466 (376,952 ) 2,814,288 Operating income 50,370 268,712 118,454 — 437,536 Debt expense (98,496 ) (89,048 ) (8,730 ) 96,396 (99,878 ) Other income 94,258 388 504 (96,396 ) (1,246 ) Income tax expense 18,395 99,927 (1,694 ) — 116,628 Equity earnings in subsidiaries 156,385 76,260 — (232,645 ) — Net income 184,122 156,385 111,922 (232,645 ) 219,784 Less: Net income attributable to noncontrolling interests — — — (35,662 ) (35,662 ) Net income attributable to DaVita HealthCare Partners Inc. $ 184,122 $ 156,385 $ 111,922 $ (268,307 ) $ 184,122 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners Inc. subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 4,901,959 $ 2,254,624 $ (107,155 ) $ 7,049,428 Less: Provision for uncollectible accounts — (212,816 ) (101,765 ) — (314,581 ) Net patient service revenues — 4,689,143 2,152,859 (107,155 ) 6,734,847 Capitated revenues — 1,340,838 1,302,862 (148 ) 2,643,552 Other revenues 542,412 1,360,261 21,547 (1,054,371 ) 869,849 Total net revenues 542,412 7,390,242 3,477,268 (1,161,674 ) 10,248,248 Operating expenses 363,347 7,042,896 3,077,919 (1,161,674 ) 9,322,488 Operating income 179,065 347,346 399,349 — 925,760 Debt expense, including debt refinancing charges (347,719 ) (253,939 ) (30,532 ) 278,997 (353,193 ) Other income 271,847 6,780 4,632 (278,997 ) 4,262 Income tax expense 41,215 116,934 25,744 — 183,893 Equity earnings in subsidiaries 213,754 230,501 — (444,255 ) — Net income 275,732 213,754 347,705 (444,255 ) 392,936 Less: Net income attributable to noncontrolling interests — — — (117,204 ) (117,204 ) Net income attributable to DaVita HealthCare Partners Inc. $ 275,732 $ 213,754 $ 347,705 $ (561,459 ) $ 275,732 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners Inc. subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 4,622,943 $ 2,007,435 $ (86,498 ) $ 6,543,880 Less: Provision for uncollectible accounts — (169,133 ) (101,087 ) — (270,220 ) Net patient service revenues — 4,453,810 1,906,348 (86,498 ) 6,273,660 Capitated revenues — 1,261,385 1,175,354 (1,259 ) 2,435,480 Other revenues 518,468 1,241,043 17,229 (1,018,791 ) 757,949 Total net revenues 518,468 6,956,238 3,098,931 (1,106,548 ) 9,467,089 Operating expenses 358,968 6,141,200 2,710,413 (1,106,548 ) 8,104,033 Operating income 159,500 815,038 388,518 — 1,363,056 Debt expense (406,037 ) (277,854 ) (28,662 ) 302,660 (409,893 ) Other income 293,733 9,323 1,749 (302,660 ) 2,145 Income tax expense 18,826 315,473 8,067 — 342,366 Equity earnings in subsidiaries 486,724 255,690 — (742,414 ) — Net income 515,094 486,724 353,538 (742,414 ) 612,942 Less: Net income attributable to noncontrolling interests — — — (97,848 ) (97,848 ) Net income attributable to DaVita HealthCare Partners Inc. $ 515,094 $ 486,724 $ 353,538 $ (840,262 ) $ 515,094 Condensed Consolidating Statements of Comprehensive Income DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Net income $ 215,872 $ 179,926 $ 150,234 $ (284,725 ) $ 261,307 Other comprehensive loss (2,934 ) — (7,023 ) — (9,957 ) Total comprehensive income 212,938 179,926 143,211 (284,725 ) 251,350 Less: comprehensive income attributable to the noncontrolling interests — — — (45,435 ) (45,435 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 212,938 $ 179,926 $ 143,211 $ (330,160 ) $ 205,915 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Net income $ 184,122 $ 156,385 $ 111,922 $ (232,645 ) $ 219,784 Other comprehensive income (loss) 1,548 — (13,838 ) — (12,290 ) Total comprehensive income 185,670 156,385 98,084 (232,645 ) 207,494 Less: comprehensive income attributable to the noncontrolling interests — — — (35,662 ) (35,662 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 185,670 $ 156,385 $ 98,084 $ (268,307 ) $ 171,832 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners Inc. subsidiaries subsidiaries adjustments total Net income $ 275,732 $ 213,754 $ 347,705 $ (444,255 ) $ 392,936 Other comprehensive loss (9,436 ) — (19,883 ) — (29,319 ) Total comprehensive income 266,296 213,754 327,822 (444,255 ) 363,617 Less: comprehensive income attributable to the noncontrolling interests — — — (117,204 ) (117,204 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 266,296 $ 213,754 $ 327,822 $ (561,459 ) $ 246,413 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners Inc. subsidiaries subsidiaries adjustments total Net income $ 515,094 $ 486,724 $ 353,538 $ (742,414 ) $ 612,942 Other comprehensive income (loss) 2,892 — (11,871 ) — (8,979 ) Total comprehensive income 517,986 486,724 341,667 (742,414 ) 603,963 Less: comprehensive income attributable to the noncontrolling interests — — — (97,848 ) (97,848 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 517,986 $ 486,724 $ 341,667 $ (840,262 ) $ 506,115 Condensed Consolidating Balance Sheets DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated As of September 30, 2015 Partners subsidiaries subsidiaries adjustments total Cash and cash equivalents $ 721,477 $ 88,969 $ 236,973 $ — $ 1,047,419 Accounts receivable, net — 940,399 759,493 — 1,699,892 Other current assets 941,660 956,238 92,677 — 1,990,575 Total current assets 1,663,137 1,985,606 1,089,143 — 4,737,886 Property and equipment, net 204,437 1,510,820 906,661 — 2,621,918 Amortizable intangibles, net 86,336 1,690,110 50,336 — 1,826,782 Investments in subsidiaries 8,995,822 1,580,113 — (10,575,935 ) — Intercompany receivables 3,508,016 — 644,469 (4,152,485 ) — Other long-term assets and investments 59,900 54,381 106,382 — 220,663 Goodwill — 8,028,591 1,458,988 — 9,487,579 Total assets $ 14,517,648 $ 14,849,621 $ 4,255,979 $ (14,728,420 ) $ 18,894,828 Current liabilities $ 167,134 $ 1,764,955 $ 478,465 $ — $ 2,410,554 Intercompany payables — 2,725,877 1,426,608 (4,152,485 ) — Long-term debt and other long-term liabilities 8,787,905 1,362,967 244,066 — 10,394,938 Noncontrolling interests subject to put provisions 572,256 — — 324,883 897,139 Total DaVita HealthCare Partners Inc. shareholders’ equity 4,990,353 8,995,822 1,580,113 (10,575,935 ) 4,990,353 Noncontrolling interests not subject to put provisions — — 526,727 (324,883 ) 201,844 Total equity 4,990,353 8,995,822 2,106,840 (10,900,818 ) 5,192,197 Total liabilities and equity $ 14,517,648 $ 14,849,621 $ 4,255,979 $ (14,728,420 ) $ 18,894,828 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated As of December 31, 2014 Partners subsidiaries subsidiaries adjustments total Cash and cash equivalents $ 698,876 $ 77,921 $ 188,444 $ — $ 965,241 Accounts receivable, net — 915,851 609,998 — 1,525,849 Other current assets 362,672 930,093 92,942 — 1,385,707 Total current assets 1,061,548 1,923,865 891,384 — 3,876,797 Property and equipment, net 195,690 1,473,188 800,221 — 2,469,099 Amortizable intangibles, net 85,338 1,811,218 52,942 — 1,949,498 Investments in subsidiaries 8,868,335 1,561,195 — (10,429,530 ) — Intercompany receivables 3,723,454 — 564,241 (4,287,695 ) — Other long-term assets and investments 70,309 60,385 101,332 — 232,026 Goodwill — 7,958,221 1,457,074 — 9,415,295 Total assets $ 14,004,674 $ 14,788,072 $ 3,867,194 $ (14,717,225 ) $ 17,942,715 Current liabilities $ 180,977 $ 1,493,243 $ 414,432 $ — $ 2,088,652 Intercompany payables — 3,105,173 1,182,522 (4,287,695 ) — Long-term debt and other long-term liabilities 8,124,863 1,321,321 217,603 — 9,663,787 Noncontrolling interests subject to put provisions 528,321 — — 301,644 829,965 Total DaVita HealthCare Partners Inc. shareholders’ equity 5,170,513 8,868,335 1,561,195 (10,429,530 ) 5,170,513 Noncontrolling interests not subject to put provisions — — 491,442 (301,644 ) 189,798 Total equity 5,170,513 8,868,335 2,052,637 (10,731,174 ) 5,360,311 Total liabilities and equity $ 14,004,674 $ 14,788,072 $ 3,867,194 $ (14,717,225 ) $ 17,942,715 Condensed Consolidating Statements of Cash Flows DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Cash flows from operating activities: Net income $ 275,732 $ 213,754 $ 347,705 $ (444,255 ) $ 392,936 Changes in operating assets and liabilities and non-cash items included in net income (187,876 ) 441,752 29,460 444,255 727,591 Net cash provided by operating activities 87,856 655,506 377,165 — 1,120,527 Cash flows from investing activities: Additions of property and equipment, net (39,448 ) (222,447 ) (200,318 ) (462,213 ) Acquisitions — (73,339 ) (17,370 ) (90,709 ) Proceeds from asset and business sales — 6,865 — 6,865 (Purchases) proceeds from investment sales and other items (587,583 ) 1,513 (18,257 ) (604,327 ) Net cash used in investing activities (627,031 ) (287,408 ) (235,945 ) — (1,150,384 ) Cash flows from financing activities: Long-term debt and related financing costs, net 661,260 (13,183 ) (8,760 ) 639,317 Intercompany borrowing 304,623 (320,262 ) 15,639 — Other items (404,107 ) (23,605 ) (97,726 ) (525,438 ) Net cash provided by (used in) financing activities 561,776 (357,050 ) (90,847 ) — 113,879 Effect of exchange rate changes on cash — — (1,844 ) — (1,844 ) Net increase in cash and cash equivalents 22,601 11,048 48,529 82,178 Cash and cash equivalents at beginning of period 698,876 77,921 188,444 965,241 Cash and cash equivalents at end of period $ 721,477 $ 88,969 $ 236,973 $ — $ 1,047,419 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Cash flows from operating activities: Net income $ 515,094 $ 486,724 $ 353,538 $ (742,414 ) $ 612,942 Changes in operating assets and liabilities and non-cash items included in net income (479,441 ) 578,778 74,705 742,414 916,456 Net cash provided by operating activities 35,653 1,065,502 428,243 — 1,529,398 Cash flows from investing activities: Additions of property and equipment, net (37,752 ) (215,072 ) (190,683 ) (443,507 ) Acquisitions — (204,670 ) (13,447 ) (218,117 ) Proceeds from asset sales — 3,620 — 3,620 Purchases of investments and other items (137,313 ) (33,111 ) (2,757 ) (173,181 ) Net cash used in investing activities (175,065 ) (449,233 ) (206,887 ) — (831,185 ) Cash flows from financing activities: Long-term debt and related financing costs, net 40,250 (9,247 ) 295 31,298 Intercompany borrowing 759,648 (622,853 ) (136,795 ) — Other items (74,955 ) (8,292 ) (67,060 ) (150,307 ) Net cash provided by (used in) financing activities 724,943 (640,392 ) (203,560 ) — (119,009 ) Effect of exchange rate changes on cash 1,582 1,582 Net increase (decrease) in cash and cash equivalents 585,531 (24,123 ) 19,378 580,786 Cash and cash equivalents at beginning of period 602,188 151,454 192,607 946,249 Cash and cash equivalents at end of period $ 1,187,719 $ 127,331 $ 211,985 $ — $ 1,527,035

Supplemental data

Supplemental data	9 Months Ended
	Sep. 30, 2015
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Supplemental data	2 1 . Supplemental data The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes. Condensed Consolidating Statements of Income Company and Consolidated Physician Unrestricted Restricted For the nine months ended September 30, 2015 Total Groups Subsidiaries Subsidiaries (1) Patient service operating revenues $ 7,049,428 $ 98,305 $ — $ 6,951,123 Less: Provision for uncollectible accounts (314,581 ) (5,335 ) — (309,246 ) Net patient service operating revenues 6,734,847 92,970 — 6,641,877 Capitated revenues 2,643,552 1,242,486 — 1,401,066 Other revenues 869,849 4,132 — 865,717 Total net operating revenues 10,248,248 1,339,588 — 8,908,660 Operating expenses 9,322,488 1,287,321 (78 ) 8,035,245 Operating income 925,760 52,267 78 873,415 Debt expense, including refinancing charges (353,193 ) (6,518 ) — (346,675 ) Other income 4,262 195 — 4,067 Income tax expense 183,893 8,314 31 175,548 Net income 392,936 37,630 47 355,259 Less: Net income attributable to noncontrolling interests (117,204 ) — — (117,204 ) Net income attributable to DaVita HealthCare Partners Inc. $ 275,732 $ 37,630 $ 47 $ 238,055 (1) After elimination of the unrestricted subsidiaries and the physician groups. Condensed Consolidating Statements of Comprehensive Income Company and Consolidated Physician Unrestricted Restricted For the nine months ended September 30, 2015 Total Groups Subsidiaries Subsidiaries (1) Net income $ 392,936 $ 37,630 $ 47 $ 355,259 Other comprehensive loss (29,319 ) — — (29,319 ) Total comprehensive income 363,617 37,630 47 325,940 Less: comprehensive income attributable to the noncontrolling interests (117,204 ) — — (117,204 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 246,413 $ 37,630 $ 47 $ 208,736 (1) After elimination of the unrestricted subsidiaries and the physician groups. Condensed Consolidating Balance Sheets Company and Consolidated Physician Unrestricted Restricted As of September 30, 2015 Total Groups Subsidiaries Subsidiaries (1) Cash and cash equivalents $ 1,047,419 $ 81,730 $ — $ 965,689 Accounts receivable, net 1,699,892 336,176 — 1,363,716 Other current assets 1,990,575 17,033 — 1,973,542 Total current assets 4,737,886 434,939 — 4,302,947 Property and equipment, net 2,621,918 1,902 — 2,620,016 Amortizable intangibles, net 1,826,782 6,218 — 1,820,564 Other long-term assets 220,663 69,010 2,889 148,764 Goodwill 9,487,579 15,967 — 9,471,612 Total assets $ 18,894,828 $ 528,036 $ 2,889 $ 18,363,903 Current liabilities $ 2,410,554 $ 249,122 $ — $ 2,161,432 Payables to parent — 172,149 2,889 (175,038 ) Long-term debt and other long-term liabilities 10,394,938 52,611 — 10,342,327 Noncontrolling interests subject to put provisions 897,139 — — 897,139 Total DaVita HealthCare Partners Inc. shareholders’ equity 4,990,353 54,154 — 4,936,199 Noncontrolling interests not subject to put provisions 201,844 — — 201,844 Shareholders’ equity 5,192,197 54,154 — 5,138,043 Total liabilities and shareholder’s equity $ 18,894,828 $ 528,036 $ 2,889 $ 18,363,903 (1) After elimination of the unrestricted subsidiaries and the physician groups. Condensed Consolidating Statements of Cash Flows Company and Consolidated Physician Unrestricted Restricted For the nine months ended September 30, 2015 Total Groups Subsidiaries Subsidiaries (1) Cash flows from operating activities: Net income $ 392,936 $ 37,630 $ 47 $ 355,259 Changes in operating and intercompany assets and liabilities and non-cash items included in net income 727,591 (57,518 ) (47 ) 785,156 Net cash provided by (used in) operating activities 1,120,527 (19,888 ) — 1,140,415 Cash flows from investing activities: Additions of property and equipment (462,213 ) (143 ) — (462,070 ) Acquisitions and divestitures, net (90,709 ) — — (90,709 ) Proceeds from discontinued operations 6,865 — — 6,865 Investments and other items (604,327 ) (1,973 ) — (602,354 ) Net cash used in investing activities (1,150,384 ) (2,116 ) — (1,148,268 ) Cash flows from financing activities: Long-term debt 639,317 — — 639,317 Intercompany — (8,714 ) — 8,714 Other items (525,438 ) — — (525,438 ) Net cash used in by financing activities 113,879 (8,714 ) — 122,593 Effect of exchange rate changes on cash (1,844 ) — — (1,844 ) Net increase (decrease) in cash 82,178 (30,718 ) — 112,896 Cash and cash equivalents at beginning of period 965,241 112,448 — 852,793 Cash and cash equivalents at end of period $ 1,047,419 $ 81,730 $ — $ 965,689 (1) After elimination of the unrestricted subsidiaries and the physician groups.

Condensed consolidated interi29

Condensed consolidated interim financial statements (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Accounts receivable	Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the ultimate collectability of the Company’s accounts receivable, the Company analyzes its historical cash collection experience and trends for each of its government payors and commercial payors to estimate the adequacy of the allowance for doubtful accounts and the amount of the provision for uncollectible accounts. Management regularly updates its analysis based upon the most recent information available to determine its current provision for uncollectible accounts and the adequacy of its allowance for doubtful accounts. For receivables associated with dialysis patient services covered by government payors, like Medicare, the Company receives 80% of the payment directly from Medicare as established under the government’s bundled payment system and determines an appropriate allowance for doubtful accounts and provision for uncollectible accounts on the remaining balance due depending upon the Company’s estimate of the amounts ultimately collectible from other secondary coverage sources or from the patients. For receivables associated with services to patients covered by commercial payors that are either based upon contractual terms or for non-contracted health plan coverage, the Company provides an allowance for doubtful accounts by recording a provision for uncollectible accounts based upon its historical collection experience, potential inefficiencies in its billing processes and for which collectability is determined to be unlikely. Approximately 1
Goodwill	Each of the Company’s operating segments described in Note 17 to these condensed consolidated financial statements represents an individual reporting unit for goodwill impairment testing purposes, except that each sovereign jurisdiction within the Company’s international operating segments is considered a separate reporting unit. Within the U.S. dialysis and related lab services operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit. The Company has applied a similar aggregation to the HCP operations in each region, to the vascular access service centers in its vascular access services reporting unit, to the physician practices in its physician services reporting unit, and to the dialysis centers within each sovereign international jurisdiction. For the Company’s additional operating segments, no component below the operating segment level is considered a discrete business and therefore these operating segments directly constitute individual reporting units.
Long-term incentive compensation	The Company’s stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures.
Variable interest entities	The Company relies on the operating activities of certain entities that it does not directly own or control, but over which it has indirect influence and of which it is considered the primary beneficiary. These entities are subject to the consolidation guidance applicable to variable interest entities (VIEs). Under U.S. generally accepted accounting principles (GAAP), VIEs typically include (i) entities for which the entity’s equity is not sufficient to finance its activities without additional subordinated financial support; (ii) entities for which the equity holders as a group lack the power to direct the activities that most significantly influence the entity’s economic performance, the obligation to absorb the entity’s expected losses, or the right to receive the entity’s expected returns; or (iii) entities for which the voting rights of some investors are not proportional to their obligations to absorb the entity’s losses.
Fair value of financial instruments	The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company also has classified certain assets, liabilities and temporary equity that are measured at fair value into the appropriate fair value hierarchy levels as defined by the FASB.
New accounting standards	In September 2015, the FASB issued Accounting Standards Update (ASU) No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Interest – Imputation of Interest (Subtopic 835-30) – Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date.

Earnings per share (Tables)

Earnings per share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Earnings Per Share	The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share are as follows: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 Basic: Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 184,122 $ 275,732 $ 515,094 Weighted average shares outstanding during the period 214,569 214,810 215,108 214,280 Vested stock units — 1 — 1 Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger (2,194 ) (2,194 ) (2,194 ) (2,194 ) Weighted average shares for basic earnings per share calculation 212,375 212,617 212,914 212,087 Basic net income per share attributable to DaVita HealthCare Partners Inc. $ 1.02 $ 0.87 $ 1.30 $ 2.43 Diluted: Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 184,122 $ 275,732 $ 515,094 Weighted average shares outstanding during the period 214,569 214,810 215,108 214,280 Vested stock units — 1 — 1 Assumed incremental shares from stock plans 2,122 2,425 2,313 2,414 Weighted average shares for diluted earnings per share calculation 216,691 217,236 217,421 216,695 Diluted net income per share attributable to DaVita HealthCare Partners Inc. $ 1.00 $ 0.85 $ 1.27 $ 2.38 Anti-dilutive potential common shares excluded from calculation (1) 1,184 1,422 1,092 1,804 ______________ (1) Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Investments in debt and equit31

Investments in debt and equity securities and other investments (Tables)	9 Months Ended
	Sep. 30, 2015
Investments Debt And Equity Securities [Abstract]
Investments	The Company’s investments in securities consist of the following: September 30, 2015 December 31, 2014 Held to Available Held to Available maturity for sale Total maturity for sale Total Certificates of deposit and money market funds due within one year $ 921,648 $ — $ 921,648 $ 335,975 $ — $ 335,975 Investments in mutual funds and common stock — 31,343 31,343 — 28,123 28,123 $ 921,648 $ 31,343 $ 952,991 $ 335,975 $ 28,123 $ 364,098 Short-term investments $ 921,648 $ 1,200 $ 922,848 $ 335,975 $ 1,424 $ 337,399 Long-term investments — 30,143 30,143 — 26,699 26,699 $ 921,648 $ 31,343 $ 952,991 $ 335,975 $ 28,123 $ 364,098

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Goodwill by Reportable Segments	Changes in goodwill by reportable segments were as follows: Other-ancillary U.S. dialysis and services and related lab services HCP strategic initiatives Consolidated total Balance at January 1, 2014 $ 5,469,473 $ 3,516,162 $ 227,339 $ 9,212,974 Acquisitions 143,021 48,649 29,844 221,514 Divestitures (1,851 ) — — (1,851 ) Foreign currency and other adjustments — (2,277 ) (15,065 ) (17,342 ) Balance at December 31, 2014 $ 5,610,643 $ 3,562,534 $ 242,118 $ 9,415,295 Acquisitions 21,910 27,665 39,558 89,133 Divestitures — (446 ) — (446 ) Foreign currency and other adjustments — — (16,403 ) (16,403 ) Balance at September 30, 2015 $ 5,632,553 $ 3,589,753 $ 265,273 $ 9,487,579

Health care costs payable (Tabl

Health care costs payable (Tables)	9 Months Ended
	Sep. 30, 2015
Health Care Organizations [Abstract]
Components of Changes in Health Care Costs Payable	The following table shows the components of changes in health care costs payable for the nine months ended September 30, 2015: Nine months ended September 30, 2015 Health care costs payable, beginning of the period $ 214,405 Add: Components of incurred health care costs Current year 1,193,444 Prior years (1,327 ) Total incurred health care costs 1,192,117 Less: Claims paid Current year 1,008,193 Prior years 195,460 Total claims paid 1,203,653 Health care costs payable, end of the period $ 202,869

Long-term debt (Tables)

Long-term debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long-term Debt	Long-term debt was comprised of the following: September 30, December 31, 2015 2014 Senior Secured Credit Facilities: Term Loan A $ 937,500 $ 975,000 Term Loan B 3,456,250 3,482,500 Senior notes 4,500,000 3,775,000 Acquisition obligations and other notes payable 61,348 69,045 Capital lease obligations 255,897 218,097 Total debt principal outstanding 9,210,995 8,519,642 Discount on long-term debt (14,282 ) (16,208 ) 9,196,713 8,503,434 Less current portion (114,617 ) (120,154 ) $ 9,082,096 $ 8,383,280
Scheduled Maturities of Long-term Debt	Scheduled maturities of long-term debt at September 30, 2015 were as follows: 2015 (remainder of the year) 29,880 2016 119,395 2017 149,372 2018 160,391 2019 734,892 2020 58,790 Thereafter 7,958,275
Derivative Instruments	The following table summarizes the Company’s derivative instruments as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Derivatives designated as hedging Balance sheet Balance sheet instruments location Fair value location Fair value Interest rate swap agreements Other short-term liabilities $ 914 Other short-term liabilities $ 1,457 Interest rate swap agreements Other long-term assets $ — Other long-term assets $ 3,281 Interest rate cap agreements Other long-term assets $ 2,219 Other long-term assets $ 13,934
Effects of Interest Rate Swap and Cap Agreements	The following table summarizes the effects of the Company’s interest rate swap and cap agreements for the three and nine months ended September 30, 2015 and 2014: Amount of Amount of (losses) gains recognized in losses reclassified OCI on interest rate swap from accumulated and cap agreements Location of OCI into income Three months ended Nine months ended losses reclassified Three months ended Nine months ended Derivatives designated September 30, September 30, from accumulated September 30, September 30, as cash flow hedges 2015 2014 2015 2014 OCI into income 2015 2014 2015 2014 Interest rate swap agreements $ (1,128 ) $ 1,058 $ (4,798 ) $ (6,728 ) Debt expense $ (655 ) $ (795 ) $ (2,061 ) $ (11,495 ) Interest rate cap agreements (1,909 ) (178 ) (11,715 ) (5,052 ) Debt expense (609 ) (1,507 ) (1,829 ) (4,521 ) Tax benefit (expense) 1,186 (343 ) 6,449 4,603 493 899 1,518 6,257 Total $ (1,851 ) $ 537 $ (10,064 ) $ (7,177 ) $ (771 ) $ (1,403 ) $ (2,372 ) $ (9,759 )

Comprehensive income (Tables)

Comprehensive income (Tables)	9 Months Ended
	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Comprehensive income	For the three months ended For the nine months ended September 30, 2015 September 30, 2015 Interest Foreign Accumulated Interest Foreign Accumulated rate swap currency other rate swap currency other and cap Investment translation comprehensive and cap Investment translation comprehensive agreements securities adjustments (loss) income agreements securities adjustments (loss) income Beginning balance $ (8,407 ) $ 3,261 $ (39,233 ) $ (44,379 ) $ (1,795 ) $ 3,151 $ (26,373 ) $ (25,017 ) Unrealized losses (3,037 ) (2,325 ) (7,023 ) (12,385 ) (16,513 ) (1,864 ) (19,883 ) (38,260 ) Related income tax benefit 1,186 674 — 1,860 6,449 496 — 6,945 (1,851 ) (1,651 ) (7,023 ) (10,525 ) (10,064 ) (1,368 ) (19,883 ) (31,315 ) Reclassification from accumulated other comprehensive income into net income 1,264 (333 ) — 931 3,890 (617 ) — 3,273 Related income tax (expense) benefit (493 ) 130 — (363 ) (1,518 ) 241 — (1,277 ) 771 (203 ) — 568 2,372 (376 ) — 1,996 Ending balance $ (9,487 ) $ 1,407 $ (46,256 ) $ (54,336 ) $ (9,487 ) $ 1,407 $ (46,256 ) $ (54,336 ) For the three months ended For the nine months ended September 30, 2014 September 30, 2014 Interest Foreign Accumulated Interest Foreign Accumulated rate swap currency other rate swap currency other and cap Investment translation comprehensive and cap Investment translation comprehensive agreements securities adjustments income (loss) agreements securities adjustments (loss) income Beginning balance $ (1,702 ) $ 3,822 $ (1,454 ) $ 666 $ (2,344 ) $ 3,120 $ (3,421 ) $ (2,645 ) Unrealized gains (losses) 880 (567 ) (13,838 ) (13,525 ) (11,780 ) 838 (11,871 ) (22,813 ) Related income tax (expense) benefit (343 ) 175 — (168 ) 4,603 (321 ) — 4,282 537 (392 ) (13,838 ) (13,693 ) (7,177 ) 517 (11,871 ) (18,531 ) Reclassification from accumulated other comprehensive income into net income 2,302 — — 2,302 16,016 (340 ) — 15,676 Related income tax (expense) benefit (899 ) — — (899 ) (6,257 ) 133 — (6,124 ) 1,403 — — 1,403 9,759 (207 ) — 9,552 Ending balance $ 238 $ 3,430 $ (15,292 ) $ (11,624 ) $ 238 $ 3,430 $ (15,292 ) $ (11,624 )

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Aggregate Purchase Cost Allocations	The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values: Nine months ended September 30, 2015 Current assets $ 3,324 Property and equipment 12,040 Amortizable intangible and other long-term assets 8,478 Goodwill 89,133 Long-term deferred income taxes (750 ) Noncontrolling interests assumed (18,898 ) Liabilities assumed (1,788 ) Aggregate purchase price $ 91,539
Reconciliation of Changes in Contingent Earn-Out Obligations	The following is a reconciliation of changes in the contingent earn-out obligations for the nine months ended September 30, 2015: Beginning balance, January 1, 2015 $ 39,129 Remeasurement of fair value for contingent earn-out obligations (2,818 ) Payments on contingent earn-out obligations (6,002 ) $ 30,309

Fair value of financial instr37

Fair value of financial instruments (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis	The following table summarizes the Company’s assets, liabilities and temporary equity measured at fair value on a recurring basis as of September 30, 2015: Quoted prices in Significant active Significant other unobservable identical assets observable inputs Total (Level 1) (Level 2) (Level 3) Assets Available-for-sale securities $ 31,343 $ 31,343 $ — $ — Interest rate cap agreements $ 2,219 $ — $ 2,219 $ — Interest rate swap agreements $ — $ — $ — $ — Funds on deposit with third parties $ 87,710 $ 87,710 $ — $ — Liabilities Contingent earn-out obligations $ 30,309 $ — $ — $ 30,309 Interest rate swap agreements $ 914 $ — $ 914 — Temporary equity Noncontrolling interests subject to put provisions $ 897,139 $ — $ — $ 897,139

Segment reporting (Tables)

Segment reporting (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income Before Income Taxes	The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 Segment net revenues: U.S. dialysis and related lab services Patient service revenues: External sources $ 2,287,329 $ 2,153,914 $ 6,679,251 $ 6,279,263 Intersegment revenues 13,630 10,701 39,078 27,617 Total dialysis and related lab services revenues 2,300,959 2,164,615 6,718,329 6,306,880 Less: Provision for uncollectible accounts (103,543 ) (91,996 ) (302,324 ) (257,687 ) Net dialysis and related lab services patient service revenues 2,197,416 2,072,619 6,416,005 6,049,193 Other revenues (1) 3,490 3,427 10,214 10,159 Total net dialysis and related lab services revenues 2,200,906 2,076,046 6,426,219 6,059,352 HCP HCP revenues: Capitated revenues 906,478 827,933 2,587,545 2,382,656 Net patient service revenues 78,938 49,783 241,385 164,081 Other revenues (2) 15,536 14,013 66,124 72,566 Intersegment capitated and other revenues 84 251 96 608 Total revenues 1,001,036 891,980 2,895,150 2,619,911 Other—Ancillary services and strategic initiatives Net patient service revenues 41,858 31,860 116,535 88,003 Capitated revenues 20,369 20,613 56,007 52,824 Other external sources 275,210 242,277 793,511 675,224 Intersegment revenues 7,385 4,995 18,079 14,287 Total ancillary services and strategic initiatives revenues 344,822 299,745 984,132 830,338 Total net segment revenues 3,546,764 3,267,771 10,305,501 9,509,601 Elimination of intersegment revenues (21,099 ) (15,947 ) (57,253 ) (42,512 ) Consolidated net revenues $ 3,525,665 $ 3,251,824 $ 10,248,248 $ 9,467,089 Segment operating margin (loss): U.S. dialysis and related lab services $ 461,899 $ 400,226 $ 795,255 $ 1,194,874 HCP 82,562 46,339 215,192 182,341 Other—Ancillary services and strategic initiatives (30,118 ) (5,502 ) (70,153 ) (5,744 ) Total segment operating margin 514,343 441,063 940,294 1,371,471 Reconciliation of segment operating margin to consolidated income before income taxes: Corporate support costs (4,975 ) (3,527 ) (14,534 ) (8,415 ) Consolidated operating income 509,368 437,536 925,760 1,363,056 Debt expense (103,481 ) (99,878 ) (305,121 ) (312,345 ) Debt redemption and refinancing charges (48,072 ) (97,548 ) Other income (loss), net 2,484 (1,246 ) 4,262 2,145 Consolidated income before income taxes $ 408,371 $ 336,412 $ 576,829 $ 955,308 (1) (2) 50
Summary of Depreciation and Amortization Expense by Segment	Depreciation and amortization expense by reportable segment is as follows: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 U.S. dialysis and related lab services $ 111,828 $ 101,870 $ 326,281 $ 297,477 HCP 43,523 42,558 129,890 126,555 Ancillary services and strategic initiatives 6,711 4,768 18,523 13,650 $ 162,062 $ 149,196 $ 474,694 $ 437,682
Summary of Assets by Segment	Summary of assets by reportable segment is as follows: September 30, December 31, 2015 2014 Segment assets U.S. dialysis and related lab services (including equity investments of $29,784 and $28,138, respectively) $ 11,752,159 $ 10,959,096 HCP (including equity investments of $16,618 and $15,393, respectively) 6,403,622 6,285,984 Other—Ancillary services and strategic initiatives (including equity investments of $21,481 and $22,106, respectively) 739,047 697,635 Consolidated assets $ 18,894,828 $ 17,942,715
Summary of Expenditures for Property and Equipment by Segment	Expenditures for property and equipment by reportable segment is as follows: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 U.S. dialysis and related lab services. $ 138,683 $ 149,247 $ 385,734 $ 399,114 HCP 18,885 6,121 36,870 16,401 Ancillary services and strategic initiatives 13,772 9,546 39,609 27,992 $ 171,340 $ 164,914 $ 462,213 $ 443,507

Changes in DaVita HealthCare 39

Changes in DaVita HealthCare Partners Inc.'s ownership interest in consolidated subsidiaries (Tables)	9 Months Ended
	Sep. 30, 2015
Noncontrolling Interest [Abstract]
Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity	The effects of changes in DaVita HealthCare Partners Inc.’s ownership interest on the Company’s equity are as follows: Three months ended Nine months ended September 30, September 30, 2015 2014 2015 2014 Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 184,122 $ 275,732 $ 515,094 (Decrease) increase in paid-in capital for sales of noncontrolling interests — (316 ) — 355 Decrease in paid-in capital for the purchase of noncontrolling interests and adjustments to ownership interest (12,094 ) (1,962 ) (20,515 ) (506 ) Net transfers to noncontrolling interests (12,094 ) (2,278 ) (20,515 ) (151 ) Net income attributable to DaVita HealthCare Partners Inc., net of transfers to noncontrolling interests $ 203,778 $ 181,844 $ 255,217 $ 514,943

Condensed consolidating finan40

Condensed consolidating financial statements (Tables)	9 Months Ended
	Sep. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Condensed Consolidating Statements of Income	Condensed Consolidating Statements of Income DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 1,656,648 $ 795,325 $ (37,939 ) $ 2,414,034 Less: Provision for uncollectible accounts — (78,494 ) (30,958 ) — (109,452 ) Net patient service revenues — 1,578,154 764,367 (37,939 ) 2,304,582 Capitated revenues — 453,766 473,196 (115 ) 926,847 Other revenues 184,561 480,412 7,869 (378,606 ) 294,236 Total net revenues 184,561 2,512,332 1,245,432 (416,660 ) 3,525,665 Operating expenses 110,935 2,244,237 1,077,785 (416,660 ) 3,016,297 Operating income 73,626 268,095 167,647 — 509,368 Debt expense, including debt refinancing charges (102,136 ) (83,037 ) (9,766 ) 91,458 (103,481 ) Other income 89,824 2,379 1,739 (91,458 ) 2,484 Income tax expense 25,368 112,310 9,386 — 147,064 Equity earnings in subsidiaries 179,926 104,799 — (284,725 ) — Net income 215,872 179,926 150,234 (284,725 ) 261,307 Less: Net income attributable to noncontrolling interests — — — (45,435 ) (45,435 ) Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 179,926 $ 150,234 $ (330,160 ) $ 215,872 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 1,592,398 $ 683,171 $ (33,036 ) $ 2,242,533 Less: Provision for uncollectible accounts — (61,973 ) (36,998 ) — (98,971 ) Net patient service revenues — 1,530,425 646,173 (33,036 ) 2,143,562 Capitated revenues — 442,472 406,926 (852 ) 848,546 Other revenues 174,226 422,733 5,821 (343,064 ) 259,716 Total net revenues 174,226 2,395,630 1,058,920 (376,952 ) 3,251,824 Operating expenses 123,856 2,126,918 940,466 (376,952 ) 2,814,288 Operating income 50,370 268,712 118,454 — 437,536 Debt expense (98,496 ) (89,048 ) (8,730 ) 96,396 (99,878 ) Other income 94,258 388 504 (96,396 ) (1,246 ) Income tax expense 18,395 99,927 (1,694 ) — 116,628 Equity earnings in subsidiaries 156,385 76,260 — (232,645 ) — Net income 184,122 156,385 111,922 (232,645 ) 219,784 Less: Net income attributable to noncontrolling interests — — — (35,662 ) (35,662 ) Net income attributable to DaVita HealthCare Partners Inc. $ 184,122 $ 156,385 $ 111,922 $ (268,307 ) $ 184,122 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners Inc. subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 4,901,959 $ 2,254,624 $ (107,155 ) $ 7,049,428 Less: Provision for uncollectible accounts — (212,816 ) (101,765 ) — (314,581 ) Net patient service revenues — 4,689,143 2,152,859 (107,155 ) 6,734,847 Capitated revenues — 1,340,838 1,302,862 (148 ) 2,643,552 Other revenues 542,412 1,360,261 21,547 (1,054,371 ) 869,849 Total net revenues 542,412 7,390,242 3,477,268 (1,161,674 ) 10,248,248 Operating expenses 363,347 7,042,896 3,077,919 (1,161,674 ) 9,322,488 Operating income 179,065 347,346 399,349 — 925,760 Debt expense, including debt refinancing charges (347,719 ) (253,939 ) (30,532 ) 278,997 (353,193 ) Other income 271,847 6,780 4,632 (278,997 ) 4,262 Income tax expense 41,215 116,934 25,744 — 183,893 Equity earnings in subsidiaries 213,754 230,501 — (444,255 ) — Net income 275,732 213,754 347,705 (444,255 ) 392,936 Less: Net income attributable to noncontrolling interests — — — (117,204 ) (117,204 ) Net income attributable to DaVita HealthCare Partners Inc. $ 275,732 $ 213,754 $ 347,705 $ (561,459 ) $ 275,732 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners Inc. subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 4,622,943 $ 2,007,435 $ (86,498 ) $ 6,543,880 Less: Provision for uncollectible accounts — (169,133 ) (101,087 ) — (270,220 ) Net patient service revenues — 4,453,810 1,906,348 (86,498 ) 6,273,660 Capitated revenues — 1,261,385 1,175,354 (1,259 ) 2,435,480 Other revenues 518,468 1,241,043 17,229 (1,018,791 ) 757,949 Total net revenues 518,468 6,956,238 3,098,931 (1,106,548 ) 9,467,089 Operating expenses 358,968 6,141,200 2,710,413 (1,106,548 ) 8,104,033 Operating income 159,500 815,038 388,518 — 1,363,056 Debt expense (406,037 ) (277,854 ) (28,662 ) 302,660 (409,893 ) Other income 293,733 9,323 1,749 (302,660 ) 2,145 Income tax expense 18,826 315,473 8,067 — 342,366 Equity earnings in subsidiaries 486,724 255,690 — (742,414 ) — Net income 515,094 486,724 353,538 (742,414 ) 612,942 Less: Net income attributable to noncontrolling interests — — — (97,848 ) (97,848 ) Net income attributable to DaVita HealthCare Partners Inc. $ 515,094 $ 486,724 $ 353,538 $ (840,262 ) $ 515,094
Condensed Consolidating Statements of Comprehensive Income	Condensed Consolidating Statements of Comprehensive Income DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Net income $ 215,872 $ 179,926 $ 150,234 $ (284,725 ) $ 261,307 Other comprehensive loss (2,934 ) — (7,023 ) — (9,957 ) Total comprehensive income 212,938 179,926 143,211 (284,725 ) 251,350 Less: comprehensive income attributable to the noncontrolling interests — — — (45,435 ) (45,435 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 212,938 $ 179,926 $ 143,211 $ (330,160 ) $ 205,915 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Net income $ 184,122 $ 156,385 $ 111,922 $ (232,645 ) $ 219,784 Other comprehensive income (loss) 1,548 — (13,838 ) — (12,290 ) Total comprehensive income 185,670 156,385 98,084 (232,645 ) 207,494 Less: comprehensive income attributable to the noncontrolling interests — — — (35,662 ) (35,662 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 185,670 $ 156,385 $ 98,084 $ (268,307 ) $ 171,832 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners Inc. subsidiaries subsidiaries adjustments total Net income $ 275,732 $ 213,754 $ 347,705 $ (444,255 ) $ 392,936 Other comprehensive loss (9,436 ) — (19,883 ) — (29,319 ) Total comprehensive income 266,296 213,754 327,822 (444,255 ) 363,617 Less: comprehensive income attributable to the noncontrolling interests — — — (117,204 ) (117,204 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 266,296 $ 213,754 $ 327,822 $ (561,459 ) $ 246,413 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners Inc. subsidiaries subsidiaries adjustments total Net income $ 515,094 $ 486,724 $ 353,538 $ (742,414 ) $ 612,942 Other comprehensive income (loss) 2,892 — (11,871 ) — (8,979 ) Total comprehensive income 517,986 486,724 341,667 (742,414 ) 603,963 Less: comprehensive income attributable to the noncontrolling interests — — — (97,848 ) (97,848 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 517,986 $ 486,724 $ 341,667 $ (840,262 ) $ 506,115
Condensed Consolidating Balance Sheets	Condensed Consolidating Balance Sheets DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated As of September 30, 2015 Partners subsidiaries subsidiaries adjustments total Cash and cash equivalents $ 721,477 $ 88,969 $ 236,973 $ — $ 1,047,419 Accounts receivable, net — 940,399 759,493 — 1,699,892 Other current assets 941,660 956,238 92,677 — 1,990,575 Total current assets 1,663,137 1,985,606 1,089,143 — 4,737,886 Property and equipment, net 204,437 1,510,820 906,661 — 2,621,918 Amortizable intangibles, net 86,336 1,690,110 50,336 — 1,826,782 Investments in subsidiaries 8,995,822 1,580,113 — (10,575,935 ) — Intercompany receivables 3,508,016 — 644,469 (4,152,485 ) — Other long-term assets and investments 59,900 54,381 106,382 — 220,663 Goodwill — 8,028,591 1,458,988 — 9,487,579 Total assets $ 14,517,648 $ 14,849,621 $ 4,255,979 $ (14,728,420 ) $ 18,894,828 Current liabilities $ 167,134 $ 1,764,955 $ 478,465 $ — $ 2,410,554 Intercompany payables — 2,725,877 1,426,608 (4,152,485 ) — Long-term debt and other long-term liabilities 8,787,905 1,362,967 244,066 — 10,394,938 Noncontrolling interests subject to put provisions 572,256 — — 324,883 897,139 Total DaVita HealthCare Partners Inc. shareholders’ equity 4,990,353 8,995,822 1,580,113 (10,575,935 ) 4,990,353 Noncontrolling interests not subject to put provisions — — 526,727 (324,883 ) 201,844 Total equity 4,990,353 8,995,822 2,106,840 (10,900,818 ) 5,192,197 Total liabilities and equity $ 14,517,648 $ 14,849,621 $ 4,255,979 $ (14,728,420 ) $ 18,894,828 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated As of December 31, 2014 Partners subsidiaries subsidiaries adjustments total Cash and cash equivalents $ 698,876 $ 77,921 $ 188,444 $ — $ 965,241 Accounts receivable, net — 915,851 609,998 — 1,525,849 Other current assets 362,672 930,093 92,942 — 1,385,707 Total current assets 1,061,548 1,923,865 891,384 — 3,876,797 Property and equipment, net 195,690 1,473,188 800,221 — 2,469,099 Amortizable intangibles, net 85,338 1,811,218 52,942 — 1,949,498 Investments in subsidiaries 8,868,335 1,561,195 — (10,429,530 ) — Intercompany receivables 3,723,454 — 564,241 (4,287,695 ) — Other long-term assets and investments 70,309 60,385 101,332 — 232,026 Goodwill — 7,958,221 1,457,074 — 9,415,295 Total assets $ 14,004,674 $ 14,788,072 $ 3,867,194 $ (14,717,225 ) $ 17,942,715 Current liabilities $ 180,977 $ 1,493,243 $ 414,432 $ — $ 2,088,652 Intercompany payables — 3,105,173 1,182,522 (4,287,695 ) — Long-term debt and other long-term liabilities 8,124,863 1,321,321 217,603 — 9,663,787 Noncontrolling interests subject to put provisions 528,321 — — 301,644 829,965 Total DaVita HealthCare Partners Inc. shareholders’ equity 5,170,513 8,868,335 1,561,195 (10,429,530 ) 5,170,513 Noncontrolling interests not subject to put provisions — — 491,442 (301,644 ) 189,798 Total equity 5,170,513 8,868,335 2,052,637 (10,731,174 ) 5,360,311 Total liabilities and equity $ 14,004,674 $ 14,788,072 $ 3,867,194 $ (14,717,225 ) $ 17,942,715
Condensed Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Cash flows from operating activities: Net income $ 275,732 $ 213,754 $ 347,705 $ (444,255 ) $ 392,936 Changes in operating assets and liabilities and non-cash items included in net income (187,876 ) 441,752 29,460 444,255 727,591 Net cash provided by operating activities 87,856 655,506 377,165 — 1,120,527 Cash flows from investing activities: Additions of property and equipment, net (39,448 ) (222,447 ) (200,318 ) (462,213 ) Acquisitions — (73,339 ) (17,370 ) (90,709 ) Proceeds from asset and business sales — 6,865 — 6,865 (Purchases) proceeds from investment sales and other items (587,583 ) 1,513 (18,257 ) (604,327 ) Net cash used in investing activities (627,031 ) (287,408 ) (235,945 ) — (1,150,384 ) Cash flows from financing activities: Long-term debt and related financing costs, net 661,260 (13,183 ) (8,760 ) 639,317 Intercompany borrowing 304,623 (320,262 ) 15,639 — Other items (404,107 ) (23,605 ) (97,726 ) (525,438 ) Net cash provided by (used in) financing activities 561,776 (357,050 ) (90,847 ) — 113,879 Effect of exchange rate changes on cash — — (1,844 ) — (1,844 ) Net increase in cash and cash equivalents 22,601 11,048 48,529 82,178 Cash and cash equivalents at beginning of period 698,876 77,921 188,444 965,241 Cash and cash equivalents at end of period $ 721,477 $ 88,969 $ 236,973 $ — $ 1,047,419 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Cash flows from operating activities: Net income $ 515,094 $ 486,724 $ 353,538 $ (742,414 ) $ 612,942 Changes in operating assets and liabilities and non-cash items included in net income (479,441 ) 578,778 74,705 742,414 916,456 Net cash provided by operating activities 35,653 1,065,502 428,243 — 1,529,398 Cash flows from investing activities: Additions of property and equipment, net (37,752 ) (215,072 ) (190,683 ) (443,507 ) Acquisitions — (204,670 ) (13,447 ) (218,117 ) Proceeds from asset sales — 3,620 — 3,620 Purchases of investments and other items (137,313 ) (33,111 ) (2,757 ) (173,181 ) Net cash used in investing activities (175,065 ) (449,233 ) (206,887 ) — (831,185 ) Cash flows from financing activities: Long-term debt and related financing costs, net 40,250 (9,247 ) 295 31,298 Intercompany borrowing 759,648 (622,853 ) (136,795 ) — Other items (74,955 ) (8,292 ) (67,060 ) (150,307 ) Net cash provided by (used in) financing activities 724,943 (640,392 ) (203,560 ) — (119,009 ) Effect of exchange rate changes on cash 1,582 1,582 Net increase (decrease) in cash and cash equivalents 585,531 (24,123 ) 19,378 580,786 Cash and cash equivalents at beginning of period 602,188 151,454 192,607 946,249 Cash and cash equivalents at end of period $ 1,187,719 $ 127,331 $ 211,985 $ — $ 1,527,035

Supplemental data (Tables)

Supplemental data (Tables)	9 Months Ended
	Sep. 30, 2015
Condensed Financial Statements Captions [Line Items]
Condensed Consolidating Statements of Income	Condensed Consolidating Statements of Income DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 1,656,648 $ 795,325 $ (37,939 ) $ 2,414,034 Less: Provision for uncollectible accounts — (78,494 ) (30,958 ) — (109,452 ) Net patient service revenues — 1,578,154 764,367 (37,939 ) 2,304,582 Capitated revenues — 453,766 473,196 (115 ) 926,847 Other revenues 184,561 480,412 7,869 (378,606 ) 294,236 Total net revenues 184,561 2,512,332 1,245,432 (416,660 ) 3,525,665 Operating expenses 110,935 2,244,237 1,077,785 (416,660 ) 3,016,297 Operating income 73,626 268,095 167,647 — 509,368 Debt expense, including debt refinancing charges (102,136 ) (83,037 ) (9,766 ) 91,458 (103,481 ) Other income 89,824 2,379 1,739 (91,458 ) 2,484 Income tax expense 25,368 112,310 9,386 — 147,064 Equity earnings in subsidiaries 179,926 104,799 — (284,725 ) — Net income 215,872 179,926 150,234 (284,725 ) 261,307 Less: Net income attributable to noncontrolling interests — — — (45,435 ) (45,435 ) Net income attributable to DaVita HealthCare Partners Inc. $ 215,872 $ 179,926 $ 150,234 $ (330,160 ) $ 215,872 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 1,592,398 $ 683,171 $ (33,036 ) $ 2,242,533 Less: Provision for uncollectible accounts — (61,973 ) (36,998 ) — (98,971 ) Net patient service revenues — 1,530,425 646,173 (33,036 ) 2,143,562 Capitated revenues — 442,472 406,926 (852 ) 848,546 Other revenues 174,226 422,733 5,821 (343,064 ) 259,716 Total net revenues 174,226 2,395,630 1,058,920 (376,952 ) 3,251,824 Operating expenses 123,856 2,126,918 940,466 (376,952 ) 2,814,288 Operating income 50,370 268,712 118,454 — 437,536 Debt expense (98,496 ) (89,048 ) (8,730 ) 96,396 (99,878 ) Other income 94,258 388 504 (96,396 ) (1,246 ) Income tax expense 18,395 99,927 (1,694 ) — 116,628 Equity earnings in subsidiaries 156,385 76,260 — (232,645 ) — Net income 184,122 156,385 111,922 (232,645 ) 219,784 Less: Net income attributable to noncontrolling interests — — — (35,662 ) (35,662 ) Net income attributable to DaVita HealthCare Partners Inc. $ 184,122 $ 156,385 $ 111,922 $ (268,307 ) $ 184,122 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners Inc. subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 4,901,959 $ 2,254,624 $ (107,155 ) $ 7,049,428 Less: Provision for uncollectible accounts — (212,816 ) (101,765 ) — (314,581 ) Net patient service revenues — 4,689,143 2,152,859 (107,155 ) 6,734,847 Capitated revenues — 1,340,838 1,302,862 (148 ) 2,643,552 Other revenues 542,412 1,360,261 21,547 (1,054,371 ) 869,849 Total net revenues 542,412 7,390,242 3,477,268 (1,161,674 ) 10,248,248 Operating expenses 363,347 7,042,896 3,077,919 (1,161,674 ) 9,322,488 Operating income 179,065 347,346 399,349 — 925,760 Debt expense, including debt refinancing charges (347,719 ) (253,939 ) (30,532 ) 278,997 (353,193 ) Other income 271,847 6,780 4,632 (278,997 ) 4,262 Income tax expense 41,215 116,934 25,744 — 183,893 Equity earnings in subsidiaries 213,754 230,501 — (444,255 ) — Net income 275,732 213,754 347,705 (444,255 ) 392,936 Less: Net income attributable to noncontrolling interests — — — (117,204 ) (117,204 ) Net income attributable to DaVita HealthCare Partners Inc. $ 275,732 $ 213,754 $ 347,705 $ (561,459 ) $ 275,732 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners Inc. subsidiaries subsidiaries adjustments total Patient service revenues $ — $ 4,622,943 $ 2,007,435 $ (86,498 ) $ 6,543,880 Less: Provision for uncollectible accounts — (169,133 ) (101,087 ) — (270,220 ) Net patient service revenues — 4,453,810 1,906,348 (86,498 ) 6,273,660 Capitated revenues — 1,261,385 1,175,354 (1,259 ) 2,435,480 Other revenues 518,468 1,241,043 17,229 (1,018,791 ) 757,949 Total net revenues 518,468 6,956,238 3,098,931 (1,106,548 ) 9,467,089 Operating expenses 358,968 6,141,200 2,710,413 (1,106,548 ) 8,104,033 Operating income 159,500 815,038 388,518 — 1,363,056 Debt expense (406,037 ) (277,854 ) (28,662 ) 302,660 (409,893 ) Other income 293,733 9,323 1,749 (302,660 ) 2,145 Income tax expense 18,826 315,473 8,067 — 342,366 Equity earnings in subsidiaries 486,724 255,690 — (742,414 ) — Net income 515,094 486,724 353,538 (742,414 ) 612,942 Less: Net income attributable to noncontrolling interests — — — (97,848 ) (97,848 ) Net income attributable to DaVita HealthCare Partners Inc. $ 515,094 $ 486,724 $ 353,538 $ (840,262 ) $ 515,094
Condensed Consolidating Statements of Comprehensive Income	Condensed Consolidating Statements of Comprehensive Income DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Net income $ 215,872 $ 179,926 $ 150,234 $ (284,725 ) $ 261,307 Other comprehensive loss (2,934 ) — (7,023 ) — (9,957 ) Total comprehensive income 212,938 179,926 143,211 (284,725 ) 251,350 Less: comprehensive income attributable to the noncontrolling interests — — — (45,435 ) (45,435 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 212,938 $ 179,926 $ 143,211 $ (330,160 ) $ 205,915 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the three months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Net income $ 184,122 $ 156,385 $ 111,922 $ (232,645 ) $ 219,784 Other comprehensive income (loss) 1,548 — (13,838 ) — (12,290 ) Total comprehensive income 185,670 156,385 98,084 (232,645 ) 207,494 Less: comprehensive income attributable to the noncontrolling interests — — — (35,662 ) (35,662 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 185,670 $ 156,385 $ 98,084 $ (268,307 ) $ 171,832 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners Inc. subsidiaries subsidiaries adjustments total Net income $ 275,732 $ 213,754 $ 347,705 $ (444,255 ) $ 392,936 Other comprehensive loss (9,436 ) — (19,883 ) — (29,319 ) Total comprehensive income 266,296 213,754 327,822 (444,255 ) 363,617 Less: comprehensive income attributable to the noncontrolling interests — — — (117,204 ) (117,204 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 266,296 $ 213,754 $ 327,822 $ (561,459 ) $ 246,413 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners Inc. subsidiaries subsidiaries adjustments total Net income $ 515,094 $ 486,724 $ 353,538 $ (742,414 ) $ 612,942 Other comprehensive income (loss) 2,892 — (11,871 ) — (8,979 ) Total comprehensive income 517,986 486,724 341,667 (742,414 ) 603,963 Less: comprehensive income attributable to the noncontrolling interests — — — (97,848 ) (97,848 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 517,986 $ 486,724 $ 341,667 $ (840,262 ) $ 506,115
Condensed Consolidating Balance Sheets	Condensed Consolidating Balance Sheets DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated As of September 30, 2015 Partners subsidiaries subsidiaries adjustments total Cash and cash equivalents $ 721,477 $ 88,969 $ 236,973 $ — $ 1,047,419 Accounts receivable, net — 940,399 759,493 — 1,699,892 Other current assets 941,660 956,238 92,677 — 1,990,575 Total current assets 1,663,137 1,985,606 1,089,143 — 4,737,886 Property and equipment, net 204,437 1,510,820 906,661 — 2,621,918 Amortizable intangibles, net 86,336 1,690,110 50,336 — 1,826,782 Investments in subsidiaries 8,995,822 1,580,113 — (10,575,935 ) — Intercompany receivables 3,508,016 — 644,469 (4,152,485 ) — Other long-term assets and investments 59,900 54,381 106,382 — 220,663 Goodwill — 8,028,591 1,458,988 — 9,487,579 Total assets $ 14,517,648 $ 14,849,621 $ 4,255,979 $ (14,728,420 ) $ 18,894,828 Current liabilities $ 167,134 $ 1,764,955 $ 478,465 $ — $ 2,410,554 Intercompany payables — 2,725,877 1,426,608 (4,152,485 ) — Long-term debt and other long-term liabilities 8,787,905 1,362,967 244,066 — 10,394,938 Noncontrolling interests subject to put provisions 572,256 — — 324,883 897,139 Total DaVita HealthCare Partners Inc. shareholders’ equity 4,990,353 8,995,822 1,580,113 (10,575,935 ) 4,990,353 Noncontrolling interests not subject to put provisions — — 526,727 (324,883 ) 201,844 Total equity 4,990,353 8,995,822 2,106,840 (10,900,818 ) 5,192,197 Total liabilities and equity $ 14,517,648 $ 14,849,621 $ 4,255,979 $ (14,728,420 ) $ 18,894,828 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated As of December 31, 2014 Partners subsidiaries subsidiaries adjustments total Cash and cash equivalents $ 698,876 $ 77,921 $ 188,444 $ — $ 965,241 Accounts receivable, net — 915,851 609,998 — 1,525,849 Other current assets 362,672 930,093 92,942 — 1,385,707 Total current assets 1,061,548 1,923,865 891,384 — 3,876,797 Property and equipment, net 195,690 1,473,188 800,221 — 2,469,099 Amortizable intangibles, net 85,338 1,811,218 52,942 — 1,949,498 Investments in subsidiaries 8,868,335 1,561,195 — (10,429,530 ) — Intercompany receivables 3,723,454 — 564,241 (4,287,695 ) — Other long-term assets and investments 70,309 60,385 101,332 — 232,026 Goodwill — 7,958,221 1,457,074 — 9,415,295 Total assets $ 14,004,674 $ 14,788,072 $ 3,867,194 $ (14,717,225 ) $ 17,942,715 Current liabilities $ 180,977 $ 1,493,243 $ 414,432 $ — $ 2,088,652 Intercompany payables — 3,105,173 1,182,522 (4,287,695 ) — Long-term debt and other long-term liabilities 8,124,863 1,321,321 217,603 — 9,663,787 Noncontrolling interests subject to put provisions 528,321 — — 301,644 829,965 Total DaVita HealthCare Partners Inc. shareholders’ equity 5,170,513 8,868,335 1,561,195 (10,429,530 ) 5,170,513 Noncontrolling interests not subject to put provisions — — 491,442 (301,644 ) 189,798 Total equity 5,170,513 8,868,335 2,052,637 (10,731,174 ) 5,360,311 Total liabilities and equity $ 14,004,674 $ 14,788,072 $ 3,867,194 $ (14,717,225 ) $ 17,942,715
Condensed Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2015 Partners subsidiaries subsidiaries adjustments total Cash flows from operating activities: Net income $ 275,732 $ 213,754 $ 347,705 $ (444,255 ) $ 392,936 Changes in operating assets and liabilities and non-cash items included in net income (187,876 ) 441,752 29,460 444,255 727,591 Net cash provided by operating activities 87,856 655,506 377,165 — 1,120,527 Cash flows from investing activities: Additions of property and equipment, net (39,448 ) (222,447 ) (200,318 ) (462,213 ) Acquisitions — (73,339 ) (17,370 ) (90,709 ) Proceeds from asset and business sales — 6,865 — 6,865 (Purchases) proceeds from investment sales and other items (587,583 ) 1,513 (18,257 ) (604,327 ) Net cash used in investing activities (627,031 ) (287,408 ) (235,945 ) — (1,150,384 ) Cash flows from financing activities: Long-term debt and related financing costs, net 661,260 (13,183 ) (8,760 ) 639,317 Intercompany borrowing 304,623 (320,262 ) 15,639 — Other items (404,107 ) (23,605 ) (97,726 ) (525,438 ) Net cash provided by (used in) financing activities 561,776 (357,050 ) (90,847 ) — 113,879 Effect of exchange rate changes on cash — — (1,844 ) — (1,844 ) Net increase in cash and cash equivalents 22,601 11,048 48,529 82,178 Cash and cash equivalents at beginning of period 698,876 77,921 188,444 965,241 Cash and cash equivalents at end of period $ 721,477 $ 88,969 $ 236,973 $ — $ 1,047,419 DaVita Non- HealthCare Guarantor Guarantor Consolidating Consolidated For the nine months ended September 30, 2014 Partners subsidiaries subsidiaries adjustments total Cash flows from operating activities: Net income $ 515,094 $ 486,724 $ 353,538 $ (742,414 ) $ 612,942 Changes in operating assets and liabilities and non-cash items included in net income (479,441 ) 578,778 74,705 742,414 916,456 Net cash provided by operating activities 35,653 1,065,502 428,243 — 1,529,398 Cash flows from investing activities: Additions of property and equipment, net (37,752 ) (215,072 ) (190,683 ) (443,507 ) Acquisitions — (204,670 ) (13,447 ) (218,117 ) Proceeds from asset sales — 3,620 — 3,620 Purchases of investments and other items (137,313 ) (33,111 ) (2,757 ) (173,181 ) Net cash used in investing activities (175,065 ) (449,233 ) (206,887 ) — (831,185 ) Cash flows from financing activities: Long-term debt and related financing costs, net 40,250 (9,247 ) 295 31,298 Intercompany borrowing 759,648 (622,853 ) (136,795 ) — Other items (74,955 ) (8,292 ) (67,060 ) (150,307 ) Net cash provided by (used in) financing activities 724,943 (640,392 ) (203,560 ) — (119,009 ) Effect of exchange rate changes on cash 1,582 1,582 Net increase (decrease) in cash and cash equivalents 585,531 (24,123 ) 19,378 580,786 Cash and cash equivalents at beginning of period 602,188 151,454 192,607 946,249 Cash and cash equivalents at end of period $ 1,187,719 $ 127,331 $ 211,985 $ — $ 1,527,035
Additional Reporting Entities
Condensed Financial Statements Captions [Line Items]
Condensed Consolidating Statements of Income	Condensed Consolidating Statements of Income Company and Consolidated Physician Unrestricted Restricted For the nine months ended September 30, 2015 Total Groups Subsidiaries Subsidiaries (1) Patient service operating revenues $ 7,049,428 $ 98,305 $ — $ 6,951,123 Less: Provision for uncollectible accounts (314,581 ) (5,335 ) — (309,246 ) Net patient service operating revenues 6,734,847 92,970 — 6,641,877 Capitated revenues 2,643,552 1,242,486 — 1,401,066 Other revenues 869,849 4,132 — 865,717 Total net operating revenues 10,248,248 1,339,588 — 8,908,660 Operating expenses 9,322,488 1,287,321 (78 ) 8,035,245 Operating income 925,760 52,267 78 873,415 Debt expense, including refinancing charges (353,193 ) (6,518 ) — (346,675 ) Other income 4,262 195 — 4,067 Income tax expense 183,893 8,314 31 175,548 Net income 392,936 37,630 47 355,259 Less: Net income attributable to noncontrolling interests (117,204 ) — — (117,204 ) Net income attributable to DaVita HealthCare Partners Inc. $ 275,732 $ 37,630 $ 47 $ 238,055 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income	Condensed Consolidating Statements of Comprehensive Income Company and Consolidated Physician Unrestricted Restricted For the nine months ended September 30, 2015 Total Groups Subsidiaries Subsidiaries (1) Net income $ 392,936 $ 37,630 $ 47 $ 355,259 Other comprehensive loss (29,319 ) — — (29,319 ) Total comprehensive income 363,617 37,630 47 325,940 Less: comprehensive income attributable to the noncontrolling interests (117,204 ) — — (117,204 ) Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 246,413 $ 37,630 $ 47 $ 208,736 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets	Condensed Consolidating Balance Sheets Company and Consolidated Physician Unrestricted Restricted As of September 30, 2015 Total Groups Subsidiaries Subsidiaries (1) Cash and cash equivalents $ 1,047,419 $ 81,730 $ — $ 965,689 Accounts receivable, net 1,699,892 336,176 — 1,363,716 Other current assets 1,990,575 17,033 — 1,973,542 Total current assets 4,737,886 434,939 — 4,302,947 Property and equipment, net 2,621,918 1,902 — 2,620,016 Amortizable intangibles, net 1,826,782 6,218 — 1,820,564 Other long-term assets 220,663 69,010 2,889 148,764 Goodwill 9,487,579 15,967 — 9,471,612 Total assets $ 18,894,828 $ 528,036 $ 2,889 $ 18,363,903 Current liabilities $ 2,410,554 $ 249,122 $ — $ 2,161,432 Payables to parent — 172,149 2,889 (175,038 ) Long-term debt and other long-term liabilities 10,394,938 52,611 — 10,342,327 Noncontrolling interests subject to put provisions 897,139 — — 897,139 Total DaVita HealthCare Partners Inc. shareholders’ equity 4,990,353 54,154 — 4,936,199 Noncontrolling interests not subject to put provisions 201,844 — — 201,844 Shareholders’ equity 5,192,197 54,154 — 5,138,043 Total liabilities and shareholder’s equity $ 18,894,828 $ 528,036 $ 2,889 $ 18,363,903 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows Company and Consolidated Physician Unrestricted Restricted For the nine months ended September 30, 2015 Total Groups Subsidiaries Subsidiaries (1) Cash flows from operating activities: Net income $ 392,936 $ 37,630 $ 47 $ 355,259 Changes in operating and intercompany assets and liabilities and non-cash items included in net income 727,591 (57,518 ) (47 ) 785,156 Net cash provided by (used in) operating activities 1,120,527 (19,888 ) — 1,140,415 Cash flows from investing activities: Additions of property and equipment (462,213 ) (143 ) — (462,070 ) Acquisitions and divestitures, net (90,709 ) — — (90,709 ) Proceeds from discontinued operations 6,865 — — 6,865 Investments and other items (604,327 ) (1,973 ) — (602,354 ) Net cash used in investing activities (1,150,384 ) (2,116 ) — (1,148,268 ) Cash flows from financing activities: Long-term debt 639,317 — — 639,317 Intercompany — (8,714 ) — 8,714 Other items (525,438 ) — — (525,438 ) Net cash used in by financing activities 113,879 (8,714 ) — 122,593 Effect of exchange rate changes on cash (1,844 ) — — (1,844 ) Net increase (decrease) in cash 82,178 (30,718 ) — 112,896 Cash and cash equivalents at beginning of period 965,241 112,448 — 852,793 Cash and cash equivalents at end of period $ 1,047,419 $ 81,730 $ — $ 965,689 (1) After elimination of the unrestricted subsidiaries and the physician groups.

Reconciliations of Numerators a

Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Basic:
Net income attributable to DaVita HealthCare Partners Inc.		$ 215,872	$ 184,122	$ 275,732	$ 515,094
Weighted average shares outstanding during the period		214,569,000	214,810,000	215,108,000	214,280,000
Vested stock units			1,000		1,000
Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger		(2,194,000)	(2,194,000)	(2,194,000)	(2,194,000)
Weighted average shares for basic earnings per share calculation		212,374,897	212,617,238	212,914,126	212,086,735
Basic net income per share attributable to DaVita HealthCare Partners Inc.		$ 1.02	$ 0.87	$ 1.30	$ 2.43
Diluted:
Net income attributable to DaVita HealthCare Partners Inc.		$ 215,872	$ 184,122	$ 275,732	$ 515,094
Weighted average shares outstanding during the period		214,569,000	214,810,000	215,108,000	214,280,000
Vested stock units			1,000		1,000
Assumed incremental shares from stock plans		2,122,000	2,425,000	2,313,000	2,414,000
Weighted average shares for diluted earnings per share calculation		216,691,461	217,236,493	217,421,213	216,695,033
Diluted net income per share attributable to DaVita HealthCare Partners Inc.		$ 1	$ 0.85	$ 1.27	$ 2.38
Anti-dilutive potential common shares excluded from calculation	[1]	1,184,000	1,422,000	1,092,000	1,804,000
[1]	Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Accounts Receivable - Additiona

Accounts Receivable - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Accounts Notes And Loans Receivable [Line Items]
Percentage of outstanding patient accounts receivables to be reserved as per Company's policy	100.00%
Account receivable outstanding, number of months	3 months
Increase in allowance for doubtful accounts	$ 19,176
Government-based Programs, Medicare and Medicaid | Accounts Receivable
Accounts Notes And Loans Receivable [Line Items]
Percentage of accounts receivable due	80.00%
Health Care Patient | Accounts Receivable
Accounts Notes And Loans Receivable [Line Items]
Percentage of accounts receivable due	1.00%

Investments (Detail)

Investments (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Investment Holdings [Line Items]
Held to maturity	$ 921,648	$ 335,975
Available for sale	31,343	28,123
Total	952,991	364,098
Held to maturity, short-term investments	921,648	335,975
Available for sale, short-term investments	1,200	1,424
Total, short-term investments	922,848	337,399
Available for sale, long-term investments	30,143	26,699
Total, long-term investments	30,143	26,699
Certificates of deposit and money market funds
Investment Holdings [Line Items]
Held to maturity	921,648	335,975
Total	921,648	335,975
Investments in mutual funds and common stock
Investment Holdings [Line Items]
Available for sale, equity securities	31,343	28,123
Total	$ 31,343	$ 28,123

Investments in Debt and Equit45

Investments in Debt and Equity Securities and Other Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Investment Holdings [Line Items]
Available for sale investments gross pre-tax unrealized gain (loss)	$ 2,700		$ 2,700		$ 4,976
Unrealized gain (losses) on investments, net of tax	(1,651)	$ (392)	(1,368)	$ 517
Proceeds from sale of investments available for sale			1,611	1,321
Pre tax reclassification of net investment realized gain (loss) into net income			284	340
Reclassification of net investment realized gain (loss) into net income, net of tax			173	$ 207
HealthCare Partners (HCP)
Investment Holdings [Line Items]
Required minimum cash balance	54,900		54,900
Preferred Stock
Investment Holdings [Line Items]
Preferred stock, in a privately held company	$ 5,000		5,000
Certificates of deposit and money market funds
Investment Holdings [Line Items]
Unrealized gain (losses) on investments, pre tax			(1,992)
Unrealized gain (losses) on investments, net of tax			$ (1,446)

Changes in Goodwill by Reportab

Changes in Goodwill by Reportable Segments (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Goodwill [Line Items]
Beginning balance	$ 9,415,295	$ 9,212,974
Acquisitions	89,133	221,514
Divestitures	(446)	(1,851)
Foreign currency and other adjustments	(16,403)	(17,342)
Ending balance	9,487,579	9,415,295
U.S. dialysis and related lab services
Goodwill [Line Items]
Beginning balance	5,610,643	5,469,473
Acquisitions	21,910	143,021
Divestitures		(1,851)
Ending balance	5,632,553	5,610,643
HealthCare Partners (HCP)
Goodwill [Line Items]
Beginning balance	3,562,534	3,516,162
Acquisitions	27,665	48,649
Divestitures	(446)
Foreign currency and other adjustments		(2,277)
Ending balance	3,589,753	3,562,534
Other-Ancillary services and strategic initiatives
Goodwill [Line Items]
Beginning balance	242,118	227,339
Acquisitions	39,558	29,844
Foreign currency and other adjustments	(16,403)	(15,065)
Ending balance	$ 265,273	$ 242,118

Goodwill - Additional Informati

Goodwill - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015USD ($)Segment	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Goodwill [Line Items]
Goodwill	$ 9,487,579,000	$ 9,415,295,000	$ 9,212,974,000
Goodwill impairment charge description	Further reductions in HCP’s reimbursement rates or other significant adverse changes in its expected future cash flows or valuation assumptions could result in a goodwill impairment charge in the future. For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 1.8%, 1.9% and 2.1%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 4.6%, 3.4% and 3.9%, respectively.
Pre-tax goodwill impairment charge	$ 0
HealthCare Partners (HCP)
Goodwill [Line Items]
Number of reporting units | Segment	3
Goodwill	$ 3,589,753,000	$ 3,562,534,000	$ 3,516,162,000
HealthCare Partners (HCP) | Long-term Reduction of 3% Percent Operating Income
Goodwill [Line Items]
Decrease in operating income percentage used for assessment of fair values	3.00%
HealthCare Partners (HCP) | Increase In Discount Rates By 100 Basis Points
Goodwill [Line Items]
Increase in discount rates used for assessment of fair values	1.00%
HealthCare Partners (HCP) | California
Goodwill [Line Items]
Goodwill	$ 2,518,569,000
Percentage of Fair value in excess of carrying amount	15.20%
HealthCare Partners (HCP) | California | Long-term Reduction of 3% Percent Operating Income
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	(1.80%)
HealthCare Partners (HCP) | California | Increase In Discount Rates By 100 Basis Points
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	(4.60%)
HealthCare Partners (HCP) | Nevada
Goodwill [Line Items]
Goodwill	$ 520,968,000
Percentage of Fair value in excess of carrying amount	8.80%
HealthCare Partners (HCP) | Nevada | Long-term Reduction of 3% Percent Operating Income
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	(1.90%)
HealthCare Partners (HCP) | Nevada | Increase In Discount Rates By 100 Basis Points
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	(3.40%)
HealthCare Partners (HCP) | New Mexico
Goodwill [Line Items]
Goodwill	$ 71,684,000
Percentage of Fair value in excess of carrying amount	16.20%
HealthCare Partners (HCP) | New Mexico | Long-term Reduction of 3% Percent Operating Income
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	(2.10%)
HealthCare Partners (HCP) | New Mexico | Increase In Discount Rates By 100 Basis Points
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	(3.90%)

Components of Changes in Health

Components of Changes in Health Care Costs Payable (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Medical Expense And Medical Claims Payable [Line Items]
Health care costs payable, beginning of the period	$ 314,347
Less: Claims paid
Health care costs payable, end of the period	340,143
Healthcare Cost
Medical Expense And Medical Claims Payable [Line Items]
Health care costs payable, beginning of the period	214,405
Add: Components of incurred health care costs
Current year	1,193,444
Prior years	(1,327)
Total incurred health care costs	1,192,117
Less: Claims paid
Current year	1,008,193
Prior years	195,460
Total claims paid	1,203,653
Health care costs payable, end of the period	$ 202,869

Health Care Costs Payable - Add

Health Care Costs Payable - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Health Care Organizations [Abstract]
Increase (decrease) in prior year estimates of health care costs payable	$ (1,327)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Liability for unrecognized tax benefits which would impact effective tax rate if recognized	$ 36,004
Increase in liability for unrecognized tax benefits	4,127
Liability for unrecognized tax benefits	36,004	$ 31,877
Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits	$ 10,174	$ 10,123

Long-term Debt (Detail)

Long-term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Senior notes	$ 4,500,000	$ 3,775,000
Acquisition obligations and other notes payable	61,348	69,045
Capital lease obligations	255,897	218,097
Total debt principal outstanding	9,210,995	8,519,642
Discount on long-term debt	(14,282)	(16,208)
Carrying Amount of Long-Term Debt, Net of Unamortized Discount or Premium, Current and Noncurrent, Total	9,196,713	8,503,434
Less current portion	(114,617)	(120,154)
Long-term debt	9,082,096	8,383,280
Term Loan A
Debt Instrument [Line Items]
Senior Secured Credit Facilities	937,500	975,000
Term Loan B
Debt Instrument [Line Items]
Senior Secured Credit Facilities	$ 3,456,250	$ 3,482,500

Scheduled Maturities of Long-te

Scheduled Maturities of Long-term Debt (Detail) $ in Thousands	Sep. 30, 2015USD ($)
Debt Disclosure [Abstract]
2015 (remainder of the year)	$ 29,880
2,016	119,395
2,017	149,372
2,018	160,391
2,019	734,892
2,020	58,790
Thereafter	$ 7,958,275

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2015	Apr. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Unrealized loss on interest rate swap and cap agreements			$ (1,851,000)	$ 537,000	$ (10,064,000)	$ (7,177,000)
Weighted average effective interest rate			4.40%		4.40%
Weighted average effective interest rate			4.40%
Outstanding letters of credit			$ 56,000,000		$ 56,000,000
Secured by Certificate of Deposit
Debt Instrument [Line Items]
Outstanding letters of credit			1,000,000		1,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Undrawn revolving credit facilities			1,000,000,000		1,000,000,000
Letter of Credit
Debt Instrument [Line Items]
Outstanding letters of credit			$ 40,000,000		$ 40,000,000
London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
LIBOR cap rate			3.50%		3.50%
London Interbank Offered Rate (LIBOR) | Subsequent Event
Debt Instrument [Line Items]
LIBOR cap rate	3.50%
Interest rate cap agreements
Debt Instrument [Line Items]
Derivative, expiration date					Jun. 30, 2018
Interest rate agreements, notional amount			$ 3,500,000,000		$ 3,500,000,000
Fair value of assets			2,176,000		2,176,000
Unrealized loss on interest rate swap and cap agreements					$ (10,164,000)
Interest rate cap agreements | Subsequent Event
Debt Instrument [Line Items]
Derivative, expiration date	Jun. 30, 2020
Interest rate agreements, notional amount	$ 3,500,000,000
Senior Notes 5.0 Percent Due 2025
Debt Instrument [Line Items]
Senior notes, principal balance		$ 1,500,000,000
Senior notes, interest rate		5.00%
Senior notes, due date		2,025
Debt Instrument, frequency of periodic payment					The 5.0% Senior Notes pay interest on May 1 and November 1
Senior notes interest payment, first required payment date		Nov. 1, 2015
Debt instrument, redemption description					The Company may redeem up to 35% of the 5.0% Senior Notes at any time prior to May 1, 2018 at a certain specified price from the proceeds of one or more equity offerings. In addition, the Company may redeem some or all of the 5.0% Senior Notes at any time prior to May 1, 2020 at make whole redemption prices and on or after such date at certain specified redemption rates.
Senior Notes 6.625 Percent
Debt Instrument [Line Items]
Senior notes, principal balance		$ 775,000,000
Senior notes, interest rate		6.625%
Debt redemption and refinance charges					$ 48,072,000
Maximum | Senior Notes 5.0 Percent Due 2025
Debt Instrument [Line Items]
Debt Instrument, redemption price percentage		35.00%
Senior Notes Redemption Period One | Senior Notes 5.0 Percent Due 2025
Debt Instrument [Line Items]
End date of debt instrument redemption period		May 1, 2018
Senior Notes Redemption Period Two | Senior Notes 5.0 Percent Due 2025
Debt Instrument [Line Items]
End date of debt instrument redemption period		May 1, 2020
Term Loan A
Debt Instrument [Line Items]
Principal payments under Senior Secured Credit Facilities					$ 37,500,000
Term Loan A | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable interest rate margin					2.00%
Term Loan A | Interest rate swap agreements
Debt Instrument [Line Items]
Interest rate agreements, notional amount			$ 783,750,000		$ 783,750,000
Weighted average effective interest rate			2.26%		2.26%
Debt instrument, variable interest rate margin					2.00%
Derivative, expiration date					Sep. 30, 2016
Debt expense recognized					$ 2,061,000
Fair value of liability, net			$ (914,000)		(914,000)
Other comprehensive income unrealized gain loss on swaps arising during period net of tax					(4,798,000)
Unrealized pre-tax losses in other comprehensive income					$ (914,000)
Term Loan A | Interest rate swap agreements | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Fixed interest rate, lower limit			0.49%		0.49%
Fixed interest rate, upper limit			0.52%		0.52%
Term Loan A | Interest rate swap agreements | Not Designated as Hedging Instrument
Debt Instrument [Line Items]
Interest rate agreements, notional amount			$ 153,750,000		$ 153,750,000
Debt instrument, variable interest rate margin					2.00%
Term Loan B
Debt Instrument [Line Items]
Principal payments under Senior Secured Credit Facilities					$ 26,250,000
Term Loan B | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable interest rate margin					2.75%
LIBOR cap rate			2.50%		2.50%
Term Loan B | Interest rate cap agreements
Debt Instrument [Line Items]
Derivative, expiration date					Sep. 30, 2016
Debt expense recognized					$ 1,829,000
Interest rate agreements, notional amount			$ 2,735,000,000		2,735,000,000
Fair value of assets			$ 43,000		43,000
Unrealized loss on interest rate swap and cap agreements					$ (1,551,000)
Senior Secured Credit Facilities
Debt Instrument [Line Items]
Weighted average effective interest rate			3.50%		3.50%

Derivative Instruments (Detail)

Derivative Instruments (Detail) - Designated as Hedging Instrument - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Interest rate swap agreements | Other short-term liabilities
Derivative [Line Items]
Derivative liabilities, Fair value	$ 914	$ 1,457
Interest rate swap agreements | Other long-term assets
Derivative [Line Items]
Derivative assets, Fair value		3,281
Interest rate cap agreements | Other long-term assets
Derivative [Line Items]
Derivative assets, Fair value	$ 2,219	$ 13,934

Effects of Interest Rate Swap a

Effects of Interest Rate Swap and Cap Agreements (Detail) - Cash Flow Hedging - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Derivative Instruments Gain Loss [Line Items]
Amount of (losses) gains recognized in OCI on interest rate swap and cap agreements	$ (1,851)	$ 537	$ (10,064)	$ (7,177)
Amount of losses reclassified from accumulated OCI into income	(771)	(1,403)	(2,372)	(9,759)
Tax benefit (expense)
Derivative Instruments Gain Loss [Line Items]
Amount of (losses) gains recognized in OCI on interest rate swap and cap agreements	1,186	(343)	6,449	4,603
Amount of losses reclassified from accumulated OCI into income	493	899	1,518	6,257
Interest rate swap agreements
Derivative Instruments Gain Loss [Line Items]
Amount of (losses) gains recognized in OCI on interest rate swap and cap agreements	(1,128)	1,058	(4,798)	(6,728)
Interest rate swap agreements | Debt Expense (Including Refinancing Charges)
Derivative Instruments Gain Loss [Line Items]
Amount of losses reclassified from accumulated OCI into income	(655)	(795)	(2,061)	(11,495)
Interest rate cap agreements
Derivative Instruments Gain Loss [Line Items]
Amount of (losses) gains recognized in OCI on interest rate swap and cap agreements	(1,909)	(178)	(11,715)	(5,052)
Interest rate cap agreements | Debt Expense (Including Refinancing Charges)
Derivative Instruments Gain Loss [Line Items]
Amount of losses reclassified from accumulated OCI into income	$ (609)	$ (1,507)	$ (1,829)	$ (4,521)

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Vainer Private Civil Suit $ in Thousands	1 Months Ended
	Jun. 30, 2015USD ($)
Other Commitments [Line Items]
Litigation settlement amount	$ 450,000
Legal fees	$ 45,000

Noncontrolling Interests Subj57

Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Other Commitments [Line Items]
Schedule of Joint ventures to dissolve	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
Minimum
Other Commitments [Line Items]
Scheduled dissolution term of joint ventures	10 years
Maximum
Other Commitments [Line Items]
Scheduled dissolution term of joint ventures	50 years
Commitments to provide operating capital
Other Commitments [Line Items]
Other potential commitments to provide operating capital to several dialysis centers	$ 1,000

Long-term Incentive Compensat58

Long-term Incentive Compensation - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Long-term incentive program (LTIP) expense	$ 100,171	$ 88,323
Stock-based compensation expense	42,794	44,323
Estimated tax benefits recorded for stock-based compensation	14,870	16,075
Unrecognized compensation cost related to outstanding LTIP awards	145,914
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans	$ 75,635
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under performance-based cash component of LTIP costs, weighted average remaining period (in years)	1 year 1 month 6 days
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)	1 year 3 months 18 days
Tax benefits from stock award exercises	$ 31,069	$ 45,527
Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock granted	920
Aggregate grant-date fair value	$ 16,763
Weighted-average expected life (in years)	4 years 1 month 6 days
Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock granted	272
Aggregate grant-date fair value	$ 21,933
Weighted-average expected life (in years)	3 years 1 month 6 days

Share Repurchases - Additional

Share Repurchases - Additional information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Nov. 04, 2015	Sep. 30, 2015	Sep. 30, 2015	Oct. 30, 2015	Apr. 14, 2015	Nov. 04, 2010
Equity Class Of Treasury Stock [Line Items]
Purchase of treasury stock (in shares)		4,556	5,623
Purchase of treasury stock		$ 340,592	$ 424,705
Purchase of treasury stock, average price per share		$ 74.76	$ 75.53
Share repurchase program, authorized amount					$ 725,944	$ 274,056
Subsequent Event
Equity Class Of Treasury Stock [Line Items]
Purchase of treasury stock (in shares)	2
Purchase of treasury stock	$ 156
Purchase of treasury stock, average price per share	$ 71.01
Share repurchase program, outstanding authorizations available for share repurchase				$ 659,252

Comprehensive Income (Detail)

Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Comprehensive Income (Loss) [Line Items]
Beginning balance			$ (25,017)
Ending balance	$ (54,336)		(54,336)
Interest rate swaps and cap agreements
Comprehensive Income (Loss) [Line Items]
Beginning balance	(8,407)	$ (1,702)	(1,795)	$ (2,344)
Unrealized gains (losses)	(3,037)	880	(16,513)	(11,780)
Related income tax (expense) benefit	1,186	(343)	6,449	4,603
Unrealized (losses) gains net	(1,851)	537	(10,064)	(7,177)
Reclassification from accumulated other comprehensive income into net income	1,264	2,302	3,890	16,016
Related income tax (expense) benefit	(493)	(899)	(1,518)	(6,257)
Reclassification from accumulated other comprehensive income into net income net of tax	771	1,403	2,372	9,759
Ending balance	(9,487)	238	(9,487)	238
Investment securities
Comprehensive Income (Loss) [Line Items]
Beginning balance	3,261	3,822	3,151	3,120
Unrealized gains (losses)	(2,325)	(567)	(1,864)	838
Related income tax (expense) benefit	674	175	496	(321)
Unrealized (losses) gains net	(1,651)	(392)	(1,368)	517
Reclassification from accumulated other comprehensive income into net income	(333)		(617)	(340)
Related income tax (expense) benefit	130		241	133
Reclassification from accumulated other comprehensive income into net income net of tax	(203)		(376)	(207)
Ending balance	1,407	3,430	1,407	3,430
Foreign currency translation adjustments
Comprehensive Income (Loss) [Line Items]
Beginning balance	(39,233)	(1,454)	(26,373)	(3,421)
Unrealized gains (losses)	(7,023)	(13,838)	(19,883)	(11,871)
Unrealized (losses) gains net	(7,023)	(13,838)	(19,883)	(11,871)
Ending balance	(46,256)	(15,292)	(46,256)	(15,292)
Accumulated other comprehensive (loss) income
Comprehensive Income (Loss) [Line Items]
Beginning balance	(44,379)	666	(25,017)	(2,645)
Unrealized gains (losses)	(12,385)	(13,525)	(38,260)	(22,813)
Related income tax (expense) benefit	1,860	(168)	6,945	4,282
Unrealized (losses) gains net	(10,525)	(13,693)	(31,315)	(18,531)
Reclassification from accumulated other comprehensive income into net income	931	2,302	3,273	15,676
Related income tax (expense) benefit	(363)	(899)	(1,277)	(6,124)
Reclassification from accumulated other comprehensive income into net income net of tax	568	1,403	1,996	9,552
Ending balance	$ (54,336)	$ (11,624)	$ (54,336)	$ (11,624)

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) $ in Thousands	Aug. 17, 2015USD ($)ClinicStatePatient	Sep. 30, 2015USD ($)Entity	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Business Acquisition [Line Items]
Cash paid to acquire business		$ 90,709	$ 218,117
Renal Ventures Limited, LLC
Business Acquisition [Line Items]
Renal ventures interest percentage in dialysis centers	100.00%
Cash paid to acquire business	$ 415,000
Number of dialysis clinics ventures operations | Clinic	36
Number Of dialysis clinics venture operations states | State	6
Number of dialysis clinic patients | Patient	2,400
Dialysis businesses and other businesses
Business Acquisition [Line Items]
Cash paid to acquire business		90,709
Deferred purchase price obligations		$ 830
Amortizable intangible assets acquired, weighted-average estimated useful lives		9 years
Goodwill deductible for tax purposes associated with acquisitions		$ 71,566
Additional cash consideration in the form of earn-out payments		133,791
Fair value of contingent earn-out consideration		30,309		$ 39,129
Dialysis businesses and other businesses | Other short-term liabilities
Business Acquisition [Line Items]
Fair value of contingent earn-out consideration		21,915
Dialysis businesses and other businesses | Other long-term liabilities
Business Acquisition [Line Items]
Fair value of contingent earn-out consideration		$ 8,394
Dialysis businesses and other businesses | EBITDA or Operating Income Performance Targets or Quality Margins | Minimum
Business Acquisition [Line Items]
Earn out consideration payment period		1 year
Dialysis businesses and other businesses | EBITDA or Operating Income Performance Targets or Quality Margins | Maximum
Business Acquisition [Line Items]
Earn out consideration payment period		3 years
Dialysis businesses and other businesses | Non-Compete Agreements
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives		10 years
Dialysis businesses and other businesses | Trade Names
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives		3 years
Dialysis businesses and other businesses | U.S. dialysis and related lab services
Business Acquisition [Line Items]
Number of businesses acquired | Entity		6
Dialysis businesses and other businesses | Foreign dialysis and other medical businesses
Business Acquisition [Line Items]
Number of businesses acquired | Entity		7
Dialysis businesses and other businesses | Vascular access centers
Business Acquisition [Line Items]
Number of businesses acquired | Entity		3

Assets Acquired and Liabilities

Assets Acquired and Liabilities Assumed and Recognized at Acquisition Dates at Estimated Fair Values (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill	$ 9,487,579	$ 9,415,295	$ 9,212,974
Dialysis businesses and other businesses
Business Acquisition [Line Items]
Current assets	3,324
Property and equipment	12,040
Amortizable intangible and other long-term assets	8,478
Goodwill	89,133
Long-term deferred income taxes	(750)
Noncontrolling interests assumed	(18,898)
Liabilities assumed	(1,788)
Aggregate purchase price	$ 91,539

Reconciliation of Changes in Co

Reconciliation of Changes in Contingent Earn-Out Obligations (Detail) - Dialysis businesses and other businesses $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Business Acquisition Contingent Consideration [Line Items]
Beginning balance	$ 39,129
Remeasurement of fair value for contingent earn-out obligations	(2,818)
Payments on contingent earn-out obligations	(6,002)
Ending balance	$ 30,309

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Detail) - Variable Interest Entities $ in Thousands	Sep. 30, 2015USD ($)
Variable Interest Entity [Line Items]
Asset	$ 652,690
Liabilities	$ 337,476

Assets, Liabilities and Tempora

Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Assets
Available-for-sale securities	$ 31,343	$ 28,123
Fair Value, Measurements, Recurring
Assets
Available-for-sale securities	31,343
Funds on deposit with third parties	87,710
Liabilities
Contingent earn-out obligations	30,309
Interest rate swap agreements	914
Temporary equity
Noncontrolling interests subject to put provisions	897,139
Fair Value, Measurements, Recurring | Level 1
Assets
Available-for-sale securities	31,343
Funds on deposit with third parties	87,710
Fair Value, Measurements, Recurring | Level 2
Liabilities
Interest rate swap agreements	914
Fair Value, Measurements, Recurring | Level 3
Liabilities
Contingent earn-out obligations	30,309
Temporary equity
Noncontrolling interests subject to put provisions	897,139
Interest rate cap agreements | Fair Value, Measurements, Recurring
Assets
Interest rate derivative agreements	2,219
Interest rate cap agreements | Fair Value, Measurements, Recurring | Level 2
Assets
Interest rate derivative agreements	$ 2,219

Fair Value of Financial Instr66

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument, carrying amount	$ 9,210,995	$ 8,519,642
Senior Secured Credit Facilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument, carrying amount	4,393,750
Debt instrument, fair value	4,382,766
Senior Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument, carrying amount	4,500,000
Debt instrument, fair value	$ 4,459,375

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015Segment
Segment Reporting [Abstract]
Number of Operating Segments	2

Summary of Segment Net Revenues

Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income Before Income Taxes (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Patient service revenues		$ 2,414,034	$ 2,242,533	$ 7,049,428	$ 6,543,880
Less: Provision for uncollectible accounts		(109,452)	(98,971)	(314,581)	(270,220)
Net patient service revenues		2,304,582	2,143,562	6,734,847	6,273,660
Other revenues		294,236	259,716	869,849	757,949
Total net operating revenues		3,525,665	3,251,824	10,248,248	9,467,089
Capitated revenues		926,847	848,546	2,643,552	2,435,480
Operating income (loss)		509,368	437,536	925,760	1,363,056
Corporate support costs		(4,975)	(3,527)	(14,534)	(8,415)
Debt expense		(103,481)	(99,878)	(305,121)	(312,345)
Debt redemption and refinancing charges				(48,072)	(97,548)
Other income (loss), net		2,484	(1,246)	4,262	2,145
Income before income taxes		408,371	336,412	576,829	955,308
Operating Segments
Segment Reporting Information [Line Items]
Total net operating revenues		3,546,764	3,267,771	10,305,501	9,509,601
Operating income (loss)		514,343	441,063	940,294	1,371,471
Operating Segments | U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Patient service revenues		2,300,959	2,164,615	6,718,329	6,306,880
Less: Provision for uncollectible accounts		(103,543)	(91,996)	(302,324)	(257,687)
Net patient service revenues		2,197,416	2,072,619	6,416,005	6,049,193
Other revenues	[1]	3,490	3,427	10,214	10,159
Total net operating revenues		2,200,906	2,076,046	6,426,219	6,059,352
Operating income (loss)		461,899	400,226	795,255	1,194,874
Operating Segments | U.S. dialysis and related lab services | External Sources
Segment Reporting Information [Line Items]
Patient service revenues		2,287,329	2,153,914	6,679,251	6,279,263
Operating Segments | U.S. dialysis and related lab services | Intersegment Revenue
Segment Reporting Information [Line Items]
Patient service revenues		13,630	10,701	39,078	27,617
Operating Segments | HealthCare Partners (HCP)
Segment Reporting Information [Line Items]
Net patient service revenues		78,938	49,783	241,385	164,081
Other revenues	[2]	15,536	14,013	66,124	72,566
Total net operating revenues		1,001,036	891,980	2,895,150	2,619,911
Capitated revenues		906,478	827,933	2,587,545	2,382,656
Operating income (loss)		82,562	46,339	215,192	182,341
Operating Segments | HealthCare Partners (HCP) | Intersegment Revenue
Segment Reporting Information [Line Items]
Other revenues		84	251	96	608
Operating Segments | Other-Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Net patient service revenues		41,858	31,860	116,535	88,003
Total net operating revenues		344,822	299,745	984,132	830,338
Capitated revenues		20,369	20,613	56,007	52,824
Operating income (loss)		(30,118)	(5,502)	(70,153)	(5,744)
Operating Segments | Other-Ancillary services and strategic initiatives | External Sources
Segment Reporting Information [Line Items]
Other revenues		275,210	242,277	793,511	675,224
Operating Segments | Other-Ancillary services and strategic initiatives | Intersegment Revenue
Segment Reporting Information [Line Items]
Total net operating revenues		7,385	4,995	18,079	14,287
Intersegment Elimination
Segment Reporting Information [Line Items]
Total net operating revenues		$ (21,099)	$ (15,947)	$ (57,253)	$ (42,512)
[1]	Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment.
[2]	Includes payments received for medical consulting services and management fees for providing management and administrative services to an unconsolidated joint venture that provides medical services in which the Company owns a 50% interest, as well as revenue related to the maintenance of existing physician networks.

Summary of Segment Net Revenu69

Summary of Segment Net Revenues, Segment Operating income (Loss) and Reconciliation of Segment Income to Consolidated Income Before Income Taxes (Detail) (Parenthetical) (Detail)	Sep. 30, 2015
Segment Reporting [Abstract]
Percentage of ownership in unconsolidated joint ventures	50.00%

Summary of Depreciation and Amo

Summary of Depreciation and Amortization Expense by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 162,062	$ 149,196	$ 474,694	$ 437,682
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Depreciation and amortization	111,828	101,870	326,281	297,477
HealthCare Partners (HCP)
Segment Reporting Information [Line Items]
Depreciation and amortization	43,523	42,558	129,890	126,555
Other-Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 6,711	$ 4,768	$ 18,523	$ 13,650

Summary of Assets by Segment (D

Summary of Assets by Segment (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
ASSETS
Total assets	$ 18,894,828	$ 17,942,715
U.S. dialysis and related lab services
ASSETS
Total assets	11,752,159	10,959,096
HealthCare Partners (HCP)
ASSETS
Total assets	6,403,622	6,285,984
Other-Ancillary services and strategic initiatives
ASSETS
Total assets	$ 739,047	$ 697,635

Summary of Assets by Segment (P

Summary of Assets by Segment (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Equity investments	$ 67,883	$ 65,637
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Equity investments	29,784	28,138
HealthCare Partners (HCP)
Segment Reporting Information [Line Items]
Equity investments	16,618	15,393
Other-Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Equity investments	$ 21,481	$ 22,106

Summary of Expenditures for Pro

Summary of Expenditures for Property and Equipment by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Expenditures for property and equipment	$ 171,340	$ 164,914	$ 462,213	$ 443,507
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Expenditures for property and equipment	138,683	149,247	385,734	399,114
HealthCare Partners (HCP)
Segment Reporting Information [Line Items]
Expenditures for property and equipment	18,885	6,121	36,870	16,401
Other-Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Expenditures for property and equipment	$ 13,772	$ 9,546	$ 39,609	$ 27,992

Effects of Changes in DaVita In

Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net income attributable to DaVita HealthCare Partners Inc.	$ 215,872	$ 184,122	$ 275,732	$ 515,094
Net transfers to noncontrolling interests	(12,094)	(2,278)	(20,515)	(151)
Net income attributable to DaVita HealthCare Partners Inc., net of transfers to noncontrolling interests	203,778	181,844	255,217	514,943
Additional paid-in capital
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
(Decrease) increase in paid-in capital for sales of noncontrolling interests		(316)		355
Decrease in paid-in capital for the purchase of noncontrolling interests and adjustments to ownership interest	$ (12,094)	$ (1,962)	$ (20,515)	$ (506)

Condensed Consolidating Stateme

Condensed Consolidating Statements of Income (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Income Statements Captions [Line Items]
Patient service revenues	$ 2,414,034	$ 2,242,533	$ 7,049,428	$ 6,543,880
Less: Provision for uncollectible accounts	(109,452)	(98,971)	(314,581)	(270,220)
Net patient service revenues	2,304,582	2,143,562	6,734,847	6,273,660
Capitated revenues	926,847	848,546	2,643,552	2,435,480
Other revenues	294,236	259,716	869,849	757,949
Total net revenues	3,525,665	3,251,824	10,248,248	9,467,089
Operating expenses	3,016,297	2,814,288	9,322,488	8,104,033
Operating income	509,368	437,536	925,760	1,363,056
Debt expense, including debt refinancing charges	(103,481)	(99,878)	(353,193)	(409,893)
Other income	2,484	(1,246)	4,262	2,145
Income tax expense	147,064	116,628	183,893	342,366
Net income	261,307	219,784	392,936	612,942
Less: Net income attributable to noncontrolling interests	(45,435)	(35,662)	(117,204)	(97,848)
Net income attributable to DaVita HealthCare Partners Inc.	215,872	184,122	275,732	515,094
Consolidation, Eliminations
Condensed Income Statements Captions [Line Items]
Patient service revenues	(37,939)	(33,036)	(107,155)	(86,498)
Net patient service revenues	(37,939)	(33,036)	(107,155)	(86,498)
Capitated revenues	(115)	(852)	(148)	(1,259)
Other revenues	(378,606)	(343,064)	(1,054,371)	(1,018,791)
Total net revenues	(416,660)	(376,952)	(1,161,674)	(1,106,548)
Operating expenses	(416,660)	(376,952)	(1,161,674)	(1,106,548)
Debt expense, including debt refinancing charges	91,458	96,396	278,997	302,660
Other income	(91,458)	(96,396)	(278,997)	(302,660)
Equity earnings in subsidiaries	(284,725)	(232,645)	(444,255)	(742,414)
Net income	(284,725)	(232,645)	(444,255)	(742,414)
Less: Net income attributable to noncontrolling interests	(45,435)	(35,662)	(117,204)	(97,848)
Net income attributable to DaVita HealthCare Partners Inc.	(330,160)	(268,307)	(561,459)	(840,262)
DaVita HealthCare Partners Inc. | Reportable Legal Entities
Condensed Income Statements Captions [Line Items]
Other revenues	184,561	174,226	542,412	518,468
Total net revenues	184,561	174,226	542,412	518,468
Operating expenses	110,935	123,856	363,347	358,968
Operating income	73,626	50,370	179,065	159,500
Debt expense, including debt refinancing charges	(102,136)	(98,496)	(347,719)	(406,037)
Other income	89,824	94,258	271,847	293,733
Income tax expense	25,368	18,395	41,215	18,826
Equity earnings in subsidiaries	179,926	156,385	213,754	486,724
Net income	215,872	184,122	275,732	515,094
Net income attributable to DaVita HealthCare Partners Inc.	215,872	184,122	275,732	515,094
Guarantor Subsidiaries | Reportable Legal Entities
Condensed Income Statements Captions [Line Items]
Patient service revenues	1,656,648	1,592,398	4,901,959	4,622,943
Less: Provision for uncollectible accounts	(78,494)	(61,973)	(212,816)	(169,133)
Net patient service revenues	1,578,154	1,530,425	4,689,143	4,453,810
Capitated revenues	453,766	442,472	1,340,838	1,261,385
Other revenues	480,412	422,733	1,360,261	1,241,043
Total net revenues	2,512,332	2,395,630	7,390,242	6,956,238
Operating expenses	2,244,237	2,126,918	7,042,896	6,141,200
Operating income	268,095	268,712	347,346	815,038
Debt expense, including debt refinancing charges	(83,037)	(89,048)	(253,939)	(277,854)
Other income	2,379	388	6,780	9,323
Income tax expense	112,310	99,927	116,934	315,473
Equity earnings in subsidiaries	104,799	76,260	230,501	255,690
Net income	179,926	156,385	213,754	486,724
Net income attributable to DaVita HealthCare Partners Inc.	179,926	156,385	213,754	486,724
Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Income Statements Captions [Line Items]
Patient service revenues	795,325	683,171	2,254,624	2,007,435
Less: Provision for uncollectible accounts	(30,958)	(36,998)	(101,765)	(101,087)
Net patient service revenues	764,367	646,173	2,152,859	1,906,348
Capitated revenues	473,196	406,926	1,302,862	1,175,354
Other revenues	7,869	5,821	21,547	17,229
Total net revenues	1,245,432	1,058,920	3,477,268	3,098,931
Operating expenses	1,077,785	940,466	3,077,919	2,710,413
Operating income	167,647	118,454	399,349	388,518
Debt expense, including debt refinancing charges	(9,766)	(8,730)	(30,532)	(28,662)
Other income	1,739	504	4,632	1,749
Income tax expense	9,386	(1,694)	25,744	8,067
Net income	150,234	111,922	347,705	353,538
Net income attributable to DaVita HealthCare Partners Inc.	$ 150,234	$ 111,922	$ 347,705	$ 353,538

Condensed Consolidating State76

Condensed Consolidating Statements of Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Financial Statements Captions [Line Items]
Net income	$ 261,307	$ 219,784	$ 392,936	$ 612,942
Other comprehensive income (loss)	(9,957)	(12,290)	(29,319)	(8,979)
Total comprehensive income	251,350	207,494	363,617	603,963
Less: Comprehensive income attributable to noncontrolling interests	(45,435)	(35,662)	(117,204)	(97,848)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	205,915	171,832	246,413	506,115
Consolidation, Eliminations
Condensed Financial Statements Captions [Line Items]
Net income	(284,725)	(232,645)	(444,255)	(742,414)
Total comprehensive income	(284,725)	(232,645)	(444,255)	(742,414)
Less: Comprehensive income attributable to noncontrolling interests	(45,435)	(35,662)	(117,204)	(97,848)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	(330,160)	(268,307)	(561,459)	(840,262)
DaVita HealthCare Partners Inc. | Reportable Legal Entities
Condensed Financial Statements Captions [Line Items]
Net income	215,872	184,122	275,732	515,094
Other comprehensive income (loss)	(2,934)	1,548	(9,436)	2,892
Total comprehensive income	212,938	185,670	266,296	517,986
Comprehensive income attributable to DaVita HealthCare Partners Inc.	212,938	185,670	266,296	517,986
Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements Captions [Line Items]
Net income	179,926	156,385	213,754	486,724
Total comprehensive income	179,926	156,385	213,754	486,724
Comprehensive income attributable to DaVita HealthCare Partners Inc.	179,926	156,385	213,754	486,724
Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements Captions [Line Items]
Net income	150,234	111,922	347,705	353,538
Other comprehensive income (loss)	(7,023)	(13,838)	(19,883)	(11,871)
Total comprehensive income	143,211	98,084	327,822	341,667
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$ 143,211	$ 98,084	$ 327,822	$ 341,667

Condensed Consolidating Balance

Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	$ 1,047,419	$ 965,241	$ 1,527,035	$ 946,249
Accounts receivable, net	1,699,892	1,525,849
Other current assets	1,990,575	1,385,707
Total current assets	4,737,886	3,876,797
Property and equipment, net	2,621,918	2,469,099
Amortizable intangibles, net	1,826,782	1,949,498
Other long-term assets and investments	220,663	232,026
Goodwill	9,487,579	9,415,295		9,212,974
Total assets	18,894,828	17,942,715
Current liabilities	2,410,554	2,088,652
Long-term debt and other long-term liabilities	10,394,938	9,663,787
Noncontrolling interests subject to put provisions	897,139	829,965
Total DaVita HealthCare Partners Inc. shareholders’ equity	4,990,353	5,170,513
Noncontrolling interests not subject to put provisions	201,844	189,798
Total equity	5,192,197	5,360,311
Total liabilities and equity	18,894,828	17,942,715
Consolidation, Eliminations
Condensed Balance Sheet Statements Captions [Line Items]
Investments in subsidiaries	(10,575,935)	(10,429,530)
Intercompany receivables	(4,152,485)	(4,287,695)
Total assets	(14,728,420)	(14,717,225)
Intercompany payables	(4,152,485)	(4,287,695)
Noncontrolling interests subject to put provisions	324,883	301,644
Total DaVita HealthCare Partners Inc. shareholders’ equity	(10,575,935)	(10,429,530)
Noncontrolling interests not subject to put provisions	(324,883)	(301,644)
Total equity	(10,900,818)	(10,731,174)
Total liabilities and equity	(14,728,420)	(14,717,225)
DaVita HealthCare Partners Inc. | Reportable Legal Entities
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	721,477	698,876	1,187,719	602,188
Other current assets	941,660	362,672
Total current assets	1,663,137	1,061,548
Property and equipment, net	204,437	195,690
Amortizable intangibles, net	86,336	85,338
Investments in subsidiaries	8,995,822	8,868,335
Intercompany receivables	3,508,016	3,723,454
Other long-term assets and investments	59,900	70,309
Total assets	14,517,648	14,004,674
Current liabilities	167,134	180,977
Long-term debt and other long-term liabilities	8,787,905	8,124,863
Noncontrolling interests subject to put provisions	572,256	528,321
Total DaVita HealthCare Partners Inc. shareholders’ equity	4,990,353	5,170,513
Total equity	4,990,353	5,170,513
Total liabilities and equity	14,517,648	14,004,674
Guarantor Subsidiaries | Reportable Legal Entities
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	88,969	77,921	127,331	151,454
Accounts receivable, net	940,399	915,851
Other current assets	956,238	930,093
Total current assets	1,985,606	1,923,865
Property and equipment, net	1,510,820	1,473,188
Amortizable intangibles, net	1,690,110	1,811,218
Investments in subsidiaries	1,580,113	1,561,195
Other long-term assets and investments	54,381	60,385
Goodwill	8,028,591	7,958,221
Total assets	14,849,621	14,788,072
Current liabilities	1,764,955	1,493,243
Intercompany payables	2,725,877	3,105,173
Long-term debt and other long-term liabilities	1,362,967	1,321,321
Total DaVita HealthCare Partners Inc. shareholders’ equity	8,995,822	8,868,335
Total equity	8,995,822	8,868,335
Total liabilities and equity	14,849,621	14,788,072
Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	236,973	188,444	$ 211,985	$ 192,607
Accounts receivable, net	759,493	609,998
Other current assets	92,677	92,942
Total current assets	1,089,143	891,384
Property and equipment, net	906,661	800,221
Amortizable intangibles, net	50,336	52,942
Intercompany receivables	644,469	564,241
Other long-term assets and investments	106,382	101,332
Goodwill	1,458,988	1,457,074
Total assets	4,255,979	3,867,194
Current liabilities	478,465	414,432
Intercompany payables	1,426,608	1,182,522
Long-term debt and other long-term liabilities	244,066	217,603
Total DaVita HealthCare Partners Inc. shareholders’ equity	1,580,113	1,561,195
Noncontrolling interests not subject to put provisions	526,727	491,442
Total equity	2,106,840	2,052,637
Total liabilities and equity	$ 4,255,979	$ 3,867,194

Condensed Consolidating State78

Condensed Consolidating Statements of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 261,307	$ 219,784	$ 392,936	$ 612,942
Changes in operating assets and liabilities and non-cash items included in net income			727,591	916,456
Net cash provided by operating activities			1,120,527	1,529,398
Cash flows from investing activities:
Additions of property and equipment	(171,340)	(164,914)	(462,213)	(443,507)
Acquisitions			(90,709)	(218,117)
Proceeds from asset and business sales			6,865	3,620
(Purchases) proceeds from investment sales and other items			(604,327)	(173,181)
Net cash used in investing activities			(1,150,384)	(831,185)
Cash flows from financing activities:
Long-term debt and related financing costs, net			639,317	31,298
Other items			(525,438)	(150,307)
Net cash provided by (used in) financing activities			113,879	(119,009)
Effect of exchange rate changes on cash			(1,844)	1,582
Net increase in cash and cash equivalents			82,178	580,786
Cash and cash equivalents at beginning of the year			965,241	946,249
Cash and cash equivalents at end of the period	1,047,419	1,527,035	1,047,419	1,527,035
Consolidation, Eliminations
Cash flows from operating activities:
Net income	(284,725)	(232,645)	(444,255)	(742,414)
Changes in operating assets and liabilities and non-cash items included in net income			444,255	742,414
DaVita HealthCare Partners Inc. | Reportable Legal Entities
Cash flows from operating activities:
Net income	215,872	184,122	275,732	515,094
Changes in operating assets and liabilities and non-cash items included in net income			(187,876)	(479,441)
Net cash provided by operating activities			87,856	35,653
Cash flows from investing activities:
Additions of property and equipment			(39,448)	(37,752)
(Purchases) proceeds from investment sales and other items			(587,583)	(137,313)
Net cash used in investing activities			(627,031)	(175,065)
Cash flows from financing activities:
Long-term debt and related financing costs, net			661,260	40,250
Intercompany borrowing			304,623	759,648
Other items			(404,107)	(74,955)
Net cash provided by (used in) financing activities			561,776	724,943
Net increase in cash and cash equivalents			22,601	585,531
Cash and cash equivalents at beginning of the year			698,876	602,188
Cash and cash equivalents at end of the period	721,477	1,187,719	721,477	1,187,719
Guarantor Subsidiaries | Reportable Legal Entities
Cash flows from operating activities:
Net income	179,926	156,385	213,754	486,724
Changes in operating assets and liabilities and non-cash items included in net income			441,752	578,778
Net cash provided by operating activities			655,506	1,065,502
Cash flows from investing activities:
Additions of property and equipment			(222,447)	(215,072)
Acquisitions			(73,339)	(204,670)
Proceeds from asset and business sales			6,865	3,620
(Purchases) proceeds from investment sales and other items			1,513	(33,111)
Net cash used in investing activities			(287,408)	(449,233)
Cash flows from financing activities:
Long-term debt and related financing costs, net			(13,183)	(9,247)
Intercompany borrowing			(320,262)	(622,853)
Other items			(23,605)	(8,292)
Net cash provided by (used in) financing activities			(357,050)	(640,392)
Net increase in cash and cash equivalents			11,048	(24,123)
Cash and cash equivalents at beginning of the year			77,921	151,454
Cash and cash equivalents at end of the period	88,969	127,331	88,969	127,331
Non-Guarantor Subsidiaries | Reportable Legal Entities
Cash flows from operating activities:
Net income	150,234	111,922	347,705	353,538
Changes in operating assets and liabilities and non-cash items included in net income			29,460	74,705
Net cash provided by operating activities			377,165	428,243
Cash flows from investing activities:
Additions of property and equipment			(200,318)	(190,683)
Acquisitions			(17,370)	(13,447)
(Purchases) proceeds from investment sales and other items			(18,257)	(2,757)
Net cash used in investing activities			(235,945)	(206,887)
Cash flows from financing activities:
Long-term debt and related financing costs, net			(8,760)	295
Intercompany borrowing			15,639	(136,795)
Other items			(97,726)	(67,060)
Net cash provided by (used in) financing activities			(90,847)	(203,560)
Effect of exchange rate changes on cash			(1,844)	1,582
Net increase in cash and cash equivalents			48,529	19,378
Cash and cash equivalents at beginning of the year			188,444	192,607
Cash and cash equivalents at end of the period	$ 236,973	$ 211,985	$ 236,973	$ 211,985

Supplemental Data - Condensed C

Supplemental Data - Condensed Consolidating Statements of Income (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Income Statements Captions [Line Items]
Patient service operating revenues		$ 2,414,034	$ 2,242,533	$ 7,049,428	$ 6,543,880
Less: Provision for uncollectible accounts		(109,452)	(98,971)	(314,581)	(270,220)
Net patient service revenues		2,304,582	2,143,562	6,734,847	6,273,660
Capitated revenues		926,847	848,546	2,643,552	2,435,480
Other revenues		294,236	259,716	869,849	757,949
Total net revenues		3,525,665	3,251,824	10,248,248	9,467,089
Operating expenses		3,016,297	2,814,288	9,322,488	8,104,033
Operating income		509,368	437,536	925,760	1,363,056
Debt expense, including debt refinancing charges		(103,481)	(99,878)	(353,193)	(409,893)
Other income (loss), net		2,484	(1,246)	4,262	2,145
Income tax expense		147,064	116,628	183,893	342,366
Net income		261,307	219,784	392,936	612,942
Less: Net income attributable to noncontrolling interests		(45,435)	(35,662)	(117,204)	(97,848)
Net income attributable to DaVita HealthCare Partners Inc.		$ 215,872	$ 184,122	275,732	$ 515,094
Physician Groups
Condensed Income Statements Captions [Line Items]
Patient service operating revenues				98,305
Less: Provision for uncollectible accounts				(5,335)
Net patient service revenues				92,970
Capitated revenues				1,242,486
Other revenues				4,132
Total net revenues				1,339,588
Operating expenses				1,287,321
Operating income				52,267
Debt expense, including debt refinancing charges				(6,518)
Other income (loss), net				195
Income tax expense				8,314
Net income				37,630
Net income attributable to DaVita HealthCare Partners Inc.				37,630
Unrestricted Subsidiaries
Condensed Income Statements Captions [Line Items]
Operating expenses				(78)
Operating income				78
Income tax expense				31
Net income				47
Net income attributable to DaVita HealthCare Partners Inc.				47
Company and Restricted Subsidiaries
Condensed Income Statements Captions [Line Items]
Patient service operating revenues	[1]			6,951,123
Less: Provision for uncollectible accounts	[1]			(309,246)
Net patient service revenues	[1]			6,641,877
Capitated revenues	[1]			1,401,066
Other revenues	[1]			865,717
Total net revenues	[1]			8,908,660
Operating expenses	[1]			8,035,245
Operating income	[1]			873,415
Debt expense, including debt refinancing charges	[1]			(346,675)
Other income (loss), net	[1]			4,067
Income tax expense	[1]			175,548
Net income	[1]			355,259
Less: Net income attributable to noncontrolling interests	[1]			(117,204)
Net income attributable to DaVita HealthCare Partners Inc.	[1]			$ 238,055
[1]	(1) After elimination of the unrestricted subsidiaries and the physician groups.

Supplemental Data - Condensed80

Supplemental Data - Condensed Consolidating Statements of Comprehensive Income (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Financial Statements Captions [Line Items]
Net income		$ 261,307	$ 219,784	$ 392,936	$ 612,942
Other comprehensive income (loss)		(9,957)	(12,290)	(29,319)	(8,979)
Total comprehensive income		251,350	207,494	363,617	603,963
Less: Comprehensive income attributable to noncontrolling interests		(45,435)	(35,662)	(117,204)	(97,848)
Comprehensive income attributable to DaVita HealthCare Partners Inc.		$ 205,915	$ 171,832	246,413	$ 506,115
Physician Groups
Condensed Financial Statements Captions [Line Items]
Net income				37,630
Total comprehensive income				37,630
Comprehensive income attributable to DaVita HealthCare Partners Inc.				37,630
Unrestricted Subsidiaries
Condensed Financial Statements Captions [Line Items]
Net income				47
Total comprehensive income				47
Comprehensive income attributable to DaVita HealthCare Partners Inc.				47
Company and Restricted Subsidiaries
Condensed Financial Statements Captions [Line Items]
Net income	[1]			355,259
Other comprehensive income (loss)	[1]			(29,319)
Total comprehensive income	[1]			325,940
Less: Comprehensive income attributable to noncontrolling interests	[1]			(117,204)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	[1]			$ 208,736
[1]	(1) After elimination of the unrestricted subsidiaries and the physician groups.

Supplemental Data - Condensed81

Supplemental Data - Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands		Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents		$ 1,047,419	$ 965,241	$ 1,527,035	$ 946,249
Accounts receivable, net		1,699,892	1,525,849
Other current assets		1,990,575	1,385,707
Total current assets		4,737,886	3,876,797
Property and equipment, net		2,621,918	2,469,099
Amortizable intangibles, net		1,826,782	1,949,498
Other long-term assets		220,663	232,026
Goodwill		9,487,579	9,415,295		$ 9,212,974
Total assets		18,894,828	17,942,715
Current liabilities		2,410,554	2,088,652
Long-term debt and other long-term liabilities		10,394,938	9,663,787
Noncontrolling interests subject to put provisions		897,139	829,965
Total DaVita HealthCare Partners Inc. shareholders’ equity		4,990,353	5,170,513
Noncontrolling interests not subject to put provisions		201,844	189,798
Total equity		5,192,197	5,360,311
Total liabilities and equity		18,894,828	17,942,715
Physician Groups
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents		81,730	112,448
Accounts receivable, net		336,176
Other current assets		17,033
Total current assets		434,939
Property and equipment, net		1,902
Amortizable intangibles, net		6,218
Other long-term assets		69,010
Goodwill		15,967
Total assets		528,036
Current liabilities		249,122
Payables to parent		172,149
Long-term debt and other long-term liabilities		52,611
Total DaVita HealthCare Partners Inc. shareholders’ equity		54,154
Total equity		54,154
Total liabilities and equity		528,036
Unrestricted Subsidiaries
Condensed Balance Sheet Statements Captions [Line Items]
Other long-term assets		2,889
Total assets		2,889
Payables to parent		2,889
Total liabilities and equity		2,889
Company and Restricted Subsidiaries
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	[1]	965,689	$ 852,793
Accounts receivable, net	[1]	1,363,716
Other current assets	[1]	1,973,542
Total current assets	[1]	4,302,947
Property and equipment, net	[1]	2,620,016
Amortizable intangibles, net	[1]	1,820,564
Other long-term assets	[1]	148,764
Goodwill	[1]	9,471,612
Total assets	[1]	18,363,903
Current liabilities	[1]	2,161,432
Payables to parent	[1]	(175,038)
Long-term debt and other long-term liabilities	[1]	10,342,327
Noncontrolling interests subject to put provisions	[1]	897,139
Total DaVita HealthCare Partners Inc. shareholders’ equity	[1]	4,936,199
Noncontrolling interests not subject to put provisions	[1]	201,844
Total equity	[1]	5,138,043
Total liabilities and equity	[1]	$ 18,363,903
[1]	(1) After elimination of the unrestricted subsidiaries and the physician groups.

Supplemental Data - Condensed82

Supplemental Data - Condensed Consolidating Statements of Cash Flows (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income		$ 261,307	$ 219,784	$ 392,936	$ 612,942
Changes in operating and intercompany assets and liabilities and non-cash items included in net income				727,591	916,456
Net cash provided by operating activities				1,120,527	1,529,398
Cash flows from investing activities:
Additions of property and equipment		(171,340)	(164,914)	(462,213)	(443,507)
Acquisitions				(90,709)	(218,117)
Proceeds from discontinued operations				6,865	3,620
Investments and other items				(604,327)	(173,181)
Net cash used in investing activities				(1,150,384)	(831,185)
Cash flows from financing activities:
Long-term debt				639,317	31,298
Other items				(525,438)	(150,307)
Net cash provided by (used in) financing activities				113,879	(119,009)
Effect of exchange rate changes on cash				(1,844)	1,582
Net increase in cash and cash equivalents				82,178	580,786
Cash and cash equivalents at beginning of the year				965,241	946,249
Cash and cash equivalents at end of the period		1,047,419	$ 1,527,035	1,047,419	$ 1,527,035
Physician Groups
Cash flows from operating activities:
Net income				37,630
Changes in operating and intercompany assets and liabilities and non-cash items included in net income				(57,518)
Net cash provided by operating activities				(19,888)
Cash flows from investing activities:
Additions of property and equipment				(143)
Investments and other items				(1,973)
Net cash used in investing activities				(2,116)
Cash flows from financing activities:
Intercompany				(8,714)
Net cash provided by (used in) financing activities				(8,714)
Net increase in cash and cash equivalents				(30,718)
Cash and cash equivalents at beginning of the year				112,448
Cash and cash equivalents at end of the period		81,730		81,730
Unrestricted Subsidiaries
Cash flows from operating activities:
Net income				47
Changes in operating and intercompany assets and liabilities and non-cash items included in net income				(47)
Company and Restricted Subsidiaries
Cash flows from operating activities:
Net income	[1]			355,259
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	[1]			785,156
Net cash provided by operating activities	[1]			1,140,415
Cash flows from investing activities:
Additions of property and equipment	[1]			(462,070)
Acquisitions	[1]			(90,709)
Proceeds from discontinued operations	[1]			6,865
Investments and other items	[1]			(602,354)
Net cash used in investing activities	[1]			(1,148,268)
Cash flows from financing activities:
Long-term debt	[1]			639,317
Intercompany	[1]			8,714
Other items	[1]			(525,438)
Net cash provided by (used in) financing activities	[1]			122,593
Effect of exchange rate changes on cash	[1]			(1,844)
Net increase in cash and cash equivalents	[1]			112,896
Cash and cash equivalents at beginning of the year	[1]			852,793
Cash and cash equivalents at end of the period	[1]	$ 965,689		$ 965,689
[1]	(1) After elimination of the unrestricted subsidiaries and the physician groups.